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Abstract 
 
CHARACTERIZATION OF THE NEUROTROPHIC FACTOR  BRAIN DERIVED 
NEUROTROPHIC FACTOR (BDNF) IN INTESTINAL SMOOTH MUSCLE CELLS 
                                                  By Mohammad A. Al Qudah, Ph.D. 
A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. Virginia Commonwealth University, 2013                                 
Major Director: John R. Grider 
                                                  Professor, Department of Physiology  
 
Brain-derived neurotrophic factor (BDNF) belongs to the neurotrophin family of secreted 
proteins, which include in addition to BDNF, nerve growth factor (NGF) and neurotrophin 3-6 
(NT-3-6). BDNF mediates its functions by activating two cell surface receptors, pan-
neurotrophin receptor (P75NTR) and tropomyosin-related kinase B (TrkB) and their downstream 
intracellular cascades. BDNF is best known for its role in neuronal survival, regulation of 
neuronal differentiation, migration and activity-dependent synaptic plasticity. However, BDNF is 
widely expressed in non-neuronal tissues as well. The localization and the function of BDNF in 
intestinal smooth muscle cells (SMCs) are not well defined. Thus, the main purpose of the 
present study was the identification and characterization of BDNF in intestinal SMCs. Using 
 
 
xviii 
 
biochemical and molecular techniques, we have demonstrated in this study that BDNF is 
synthesized and released in rabbit intestinal longitudinal SMCs cultures. Furthermore, gut 
neuropeptides, Pituitary Adenylate Cyclase Activating Peptide (PACAP) and substance P (SP) 
increased BDNF expression and release in SMCs cultures after 24 hrs and 48 hrs incubation. We 
have also shown that intracellular Ca
2+
 levels are essential for SP stimulation of BDNF 
expression and secretion. Lastly, we have demonstrated that exogenous BDNF enhanced 
carbachol (CCh)-induced contraction of isolated longitudinal muscle strips, and this was 
inhibited  by preincubation with TrkB inhibitor K252a and PLC inhibitor U73122 sugesting that 
BDNF sensitize longitudinal SMCs to CCh by activating PLC pathway, which is normally absent  
in those muscle cells. These results provide new insight into the mechanisms of neurotrophin 
(BDNF) modulation of gut function, which may lead to new therapeutic avenues for treatment of 
gastrointestinal disorders, and explain some of the pathological changes associated with 
inflammation such as hypercontractility associated with gut infection or IBD. 
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CHAPTER 1 
INTRODUCTION AND BACKGGOUND 
 
1.1 Introduction 
Neurotrophins are a family of closely related dimeric peptides that were initially 
identified as neuronal survival factors secreted from target tissues. To date, they are 
implicated in a myriad of functions in the central and peripheral nervous systems, 
including regulation of neuronal differentiation, migration and activity-dependent 
synaptic plasticity. Four members of the mammalian neurotrophin family have been 
identified; nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5). These members share a number of 
structural and chemical properties, including more than 50% sequence homology in the 
primary sequence, approximately similar molecular weights, three disulfide bonds that 
form a cysteine knot and isoelectric points ranging from 9- 10 [1-3].  
1.1.2 History  
NGF is the first-discovered member of the neurotrophins family [4].  Rita Levi-
Montalcini together with Stanley Cohen received the noble prize in 1986 for the discovery and 
isolation of NGF, which was identified as a very powerful growth factor for sensory and 
sympathetic ganglia [5]. To-date, NGF is essential for the functional integrity of the cholinergic 
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neurons in the central nervous system and for the development and maintenance of the 
sensory nerves of the peripheral nervous system [5]. Moreover, NGF controls neurotransmitter 
and neuropeptide synthesis and release in both the central and peripheral neurons [6]. In addition 
to the pivotal role of NGF in the nervous system, there is a growing body of evidence implicating 
NGF and other neurotrophins family members in many other body organs. For example, NGF 
and its receptor have been identified in cell subpopulations of primary and secondary lymphoid 
organs and have assigned different functions in regulating immune cells and involved immune 
pathologies  [7].  
BDNF is the second member of neurotrophin family to be discovered after NFG by the 
work of Yves-Alain Barde in 1982 [8]. The  invention of the polymerase chain reaction (PCR) 
assay made it possible to clone other substances closely related to NGF with distinct albeit 
overlapping effects on neuronal survival. The extremely low abundance of those relatives 
hindered the researcher's ability to purify enough substance for amino acids sequencing. With the 
heroic effort of Brade and coworkers a distinct protein was purified from pig brain and was 
shown to promote the survival of subpopulations of neurons different from that supported by 
NGF [9]. They named the novel substance, brain derived neurotrophic factor (BDNF).  BDNF 
protein has been extensively studied and well characterized. BDNF has a complex gene structure 
with four 5’ untranslated exons (I–IV) that are associated with unique promoters and one 
common 3' exon that encodes the mature BDNF protein. The alternate splicing of these exons 
with the use of two separate polyadenylation sites, can generate at least eighteen unique BDNF 
transcripts [10]. The complex gene structure of BDNF accounts for region-specific basal and 
stimulus-evoked expression of BDNF protein during development and postnatal life [11]. BDNF 
protein has been implicated in many physiological and pathophysiological aspects of central and 
3 
  
peripheral nervous system. It has been shown to be essential for neuronal development, 
differentiation, maturation and survival. Moreover BDNF plays a pivotal role in axonal 
outgrowth, synaptic plasticity and memory formation [12]. 
Based on sequence homology and functional speculations two other mammalian 
neurotrophin members have been identified. Neurotrophin-3 was purified and cloned in 1990 by 
the work of Maisonpierre et al, two years later neurotrophin-4 was described by Hallbook and 
coworkers[9]. Despite the close structural similarities between neurotrophin family members, 
each neurotrophin has a distinct profile of functions on subpopulations of neurons in the 
peripheral and central nervous system. NT-3 has a direct effect on proliferation, survival, or 
differentiation of hippocampal progenitor cells in vivo. Moreover, it is involved in the 
mechanism of antidepressants at least through its activation of TrkB [13]. On the other hand, 
NT-4/5 and BDNF share the same receptor (TrkB) but they exhibit distinct distribution and 
functions during development [14]. There are two additional neurotrophin family members that 
are identified, neurotrophin 6 in the platyfish Xiphophorus maculatum  and neurotrophin 7 in the 
zebrafish  and the carp [15]. So far no mammalian orthologs of these NTs have been identified. 
 
1.1.3 Neurotrophin synthesis 
   All neurotrophins are synthesized as pre-pro-neurotrophins, which are subsequently 
processed and then secreted as mature proteins. The pre-sequence serves as a signal peptide to 
direct the nascent neurotrophin synthesis to the rough endoplasmic reticulum (ER) and to 
sequester the polypeptide chain into the (ER). Once the peptide is sequestered in the ER, the 
signal peptide is directly cleaved off. At this point the resulting pro-neurotrophins can form non-
covalently associated homodimers and to a lesser extent heterodimers in the ER. Here pro-
4 
  
neurotrophins can undergo additional post-translational modifications on their way through the 
Golgi apparatus and the trans-Golgi network (TGN). These include, N-linked glycosylation in 
the pro-domain, sulfatation of these N-linked oligosaccharides and cleaving of the pro-domain to 
yield the mature NTs  The TGN is an important sorting location for intracellular neurotrophins, 
where two distinct types of secretory vesicles are generated and filled with neurotrophins based 
on the mechanism of their secretion. The two main mechanisms of neurotrophin secretion are the 
constitutive and the regulated pathways. In the constitutive pathway of secretion, neurotrophins 
are packed in small diameter granules (50-100 nm) and are continuously released in a Ca
+2
 
independent fashion in the absence of any triggering stimulus. In contrast, vesicles generated in 
the regulated pathway are larger (100-300 nm), bud from the TGN, and fuse with plasma 
membrane only in a Ca
+2
 dependent manner in response to a triggering event [16]. 
It is noteworthy that conversion of pro-NT to mature NT is not a prerequisite for NT 
secretion. It has been shown that pro-NT is secreted from cell lines overexpressing NT [17] and 
can be converted to its mature form extracellulary by the action of plasmin and 
matrix metalloproteases. Interstingly, pro-NTs are biologically active, they bind efficiently to 
P75NTR receptor  and mediate opposing effects to those mediated by mature neurotrophins. 
These observations add another layer of regulation to neurotrophin function. 
 
1.1.4  Neurotrophin receptors  
Neurotrophins perform their physiological functions by binding to two distinct classes of 
cell surface receptors. The first class includes the three members of the tropomysin-related 
kinases (Trk), a subfamily of receptor tyrosine kinase. The Trk receptor has three domains; an 
extracellular domain, a single transmembrane domain and an intracellular domain that contains 
5 
  
the catalytic tyrosine kinase domain. Trk receptors are only activated by the mature 
neurotrophins where each neurotrophin family member binds specifically with one Trk receptor. 
NGF interacts with TrkA, BDNF and NT-4 interact with TrkB, and NT-3 interacts with TrkC. 
NT-3 binds to TrkA and TrkB as well, but with less affinity. Neurotrophin  binding to their 
cognate receptor induces receptor dimerization that results in kinase activation, subsequent 
receptor autophosphorylation on multiple tyrosine residues creates specific binding sites for 
intracellular adaptor proteins that are intermediates in intracellular signaling cascades. and the 
major pathways resulting from this activation are Ras, Rac, PI3-kinase, and PLCˠ1 and their 
downstream signaling cascades. Activation of Ras promotes the normal neuronal differentiation 
and survival through stimulation of mitogen-activated protein (MAP) kinase cascades. PI3-
kinase activates Akt, which accounts for many neuronal functions such as cell survival and 
axonal growth. Finally, PLC-ˠ1 activation controls many functions including activity dependent 
synaptic plasticity [1, 2]. 
The second class of neurotrophin receptors is the P75 neurotrophin receptor (P75NTR) 
which belongs to the tumor necrosis superfamily. P75NTR contains an extracellular domain that 
consists of four cysteine-rich regions, a single transmembrane domain and a death cytoplasmic 
domain. All neurotrophins interact with P75NTR with the same low affinity. P75NTR influences 
the affinity and the specificity of neurotrophins to Trk receptors by forming heterodimers with 
Trk receptors [1].  
1.1.5 BDNF is unique among neurotrophins 
Among the four members of neurotrophins, BDNF has shown unique 
characteristics and behaviors that made it attractive for researchers and a focus of myriad 
topics of investigations.  The uniqueness of BDNF comes primarily from its acute or 
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rapid action in enhancing synaptic transmission and plasticity in the adult nervous system 
[18, 19].  This function has been intensely investigated and linked with many 
physiological and pathological processes, most importantly long-term potentiation and 
memory formation [20]. Moreover, the intracellular sorting and secretion of BDNF is 
different from that of other neurotrophins.  BDNF is sorted to the regulated pathway of 
secretion and secreted in an activity-dependent manner whereas NGF and NT4 are 
secreted constitutively without activity or stimulus dependent release [10, 16, 21]. 
1.1.5.1 BDNF regulation 
BDNF gene expression is highly regulated, with tight temporal, spatial and stimulus-
specific expression. In neurons, BDNF levels are dynamically regulated in adulthood  at multiple 
layers of regulation. These include in part the regulation of BDNF gene expression, BDNF 
protein processing and intracellular trafficking that function to intricately regulate the expression 
and release of BDNF.  
The use of an alternate 5’ exon spliced of different promoters to a common 3' coding 
exon that contains the entire open reading frame for the BDNF protein along with presence of 
two polyadenylation sites, generates multiple BDNF mRNA transcripts [10].  The generation of 
multiple mRNA transcripts is differentially regulated in a stimulus-specific manner, such as 
neural activity.  For example, Ca
2+
 influx regulated-BDNF expression is regulated through 
transactivation of exon III promoter in cortical neurons; the transcription factor CaRF activates 
transcription of exon III under the control of a calcium response element (CaRE1) [22]. 
Moreover,CREB phosphorylation, which can be achieved by diverse physiological triggers, also 
controls axon III transcription [9].  
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In addition to BDNF regulation at the level of mRNA transcription, BDNF level can also 
be altered at protein level. BDNF is primarily synthesized as preproBDNF in the ER. After 
cleavage of the signal peptide, the proBDNF is translocated to the Golgi apparatus for sorting to 
either the constitutive or the regulated secretory vesicles. The BDNF sorting process is highly 
regulated and dependent on diverse factors that are cell specific. Among these factors are the 
subcellular localization of protein convertases (PCs) and their pH-optimum, consensus sequences 
in the pro and mature domains, post translational modifications and sorting receptors [17, 23]. In 
most cell types BDNF is sorted to the regulated secretory pathway, in the trans-Golgi apparatus 
BDNF is less sensitive for cleavage by PCs specific for the constitutive secretion such as furin 
[24]. Moreover, a single nucleotide polymorphism in the BDNF gene in which a valine is 
substituted to methionine in the prodomain of BDNF was found to dramatically reduce the 
regulated secretion [25]. It was found that targeting signal in the prodomain of BDNF 
surrounding the met substitution is involved in the efficient sorting to the regulated secretory 
vesicles. Furthermore, the interaction of specific amino acids encompassing the met substitution 
in BDNF proregion with the intraluminal domain of the Golgi resident sorting receptor sortilin 
accounts for the optimal trafficking of BDNF to the regulated pathway of secretion [26]. In 
addition to the sorting motif in proBDNF, the mature BDNF sequence also influences sorting. 
The three dimensional structure of mature BDNF contains a conserved sorting motif consisting 
of IIe16, Glu18, II105 and Asp106 with their side chains accessible on the protein surface.  
BDNF sorting to the regulated secretory pathway involves the electrostatic binding of the acidic 
residues of this sorting motif with the basic residues of the sorting receptor carboxypeptedaes E 
[27]. 
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Another layer of BDNF regulation is via altering the conversion of proBDNF to mature 
BDNF. ProBDNF can be converted to mature BDNF in the trans- Golgi apparatus by the action 
of members of the subtilisin-kexin family of endoproteases such as furin, or in the immature 
secretory vesicles by PCs.  In cell specific manner, proBDNF may be converted to mature BDNF 
extracellularly by plasmin through the tissue plasminogen activator dependent activation of 
plasminogen [10]. 
 
1.1.5.2 BDNF in neural disease and inflammation 
With the well established role of BDNF in learning and memory processes, alteration in 
BDNF system components have been linked to a group of diseases that share to a varying degree 
a common clinical symptom of memory loss. These pathological conditions include for example, 
schizophrenia, depression [28], Alzheimer’s disease [29], Parkinson’s disease [30] and eating 
disorders [31]. A single nucleotide polymorphism in the BDNF gene in which a valine is 
substituted for methionine in the prodomain of BDNF was found to dramatically reduce the 
regulated secretion of BDNF [32]. This genetic disorder has been found to be associated with all 
the diseases mentioned above [33]. 
There is a burgeoning body of evidence implicating BDNF in the inflammatory processes 
in different parts of the body. Numerous reports have shown increased BDNF expression at some 
stages of the inflammatory process. In airway inflammation, there is up regulation of BDNF 
mRNA and protein levels [34]. The role of BDNF in mediating different aspects of allergic 
asthma has been suggested, particularly airway hyperresponsiveness. In this regard, smooth 
muscle cells appear to be the main target for BDNF in its contribution to airway hyperreactivity 
[35, 36].  Nevertheless, BDNF and other neurotrophins may have a role in the regeneration 
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process rather than the induction of inflammation. This might be seen in the reported role of 
BDNF in enhancing the healing process in periodontitis [37].  
 
1.1.5.3 BDNF in the gut 
The role of neurotrophins in the survival and development of the gastrointestinal tract has 
been well documented [38]. Here the focus is on the physiological and pathophysiological role of 
the neurotrophin, brain derived neurotrophic factor, in gut function, which is a topic of current 
intense investigation. In comparison to the huge wealth of knowledge of the function of BDNF in 
the central and peripheral nervous system, little is known about BDNF function in the mature 
gut. 
 
1.1.5.3.a BDNF in normal gut 
The presence of BDNF and its receptors in the mature gastrointestinal tract has been 
demonstrated in several species including human, mouse and rat [39-41]. Despite the importance 
of these studies especially in supporting a role of BDNF in the adult gut, they were general 
characterizations and they did not provide detailed localization of BDNF system. A number of  
studies show that BDNF is present in mucosal cells of endocrine type and that TrkB receptor is 
present on the same or adjacent mucosal cells, indicating the possibility of autocrine/paracrine 
manners of action. Few recent studies have focused on the detailed localization of BDNF and its 
components in the gut and what functions it might have  in the mature gut [40, 42]. For example, 
studies by  Grider et al. have identified BDNF in mucosal enteroendocrine cells, intrinsic 
primary afferent neurons and extrinsic primary afferent neurons. In addition to this localization, 
they implemented BDNF functionally in the peristaltic reflex. They have shown that endogenous  
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BDNF strengthens peristaltic reflex by acting in autocrine/ paracrine fashion to augment the 
release of CGRP and 5-HT and thus augmenting the sensory limb of the reflex. Intriguingly, this 
observation was confirmed using a BDNF
+/−
 heterozygous knockout
 
mice, where the peristaltic 
reflex and release of serotonin and CGRP during the peristaltic reflex induced by mucosal 
stimulation were significantly reduced [42]. Moreover, BDNF enhanced the rate of colonic pellet 
propulsion, while its immunoneutralization reduced the rate of pellet propulsion in rat colon. 
These results provided a clear direct evidence of acute BDNF effect on gut function. BDNF is 
stored in distinct dense core vesicles ( DCV) and it is copacked with other neuropeptide 
neurotransmitters such as SP and CGRP in the same DCV [43]. In another study conducted by 
Grider’s lab, BDNF stimulates substance P release from enteric synaptosomes by acting on 
presynaptic TrkB receptors [44]. This pattern of BDNF storge provides an understanding of the 
differential  release upon stimulation. In line with these experiments, BDNF produced from 
mucosal and gut neuronal cells  has been shown to enhance the agonist induced calcium 
signaling and synaptic transmission [40]. Exposing cultured enteric neurons with BDNF alone 
did not induce any  changes in intracellular Ca
+2
 level. However, BDNF enhanced intracellular 
Ca
+2
 induced by SP and CGRP.  These recent research results support previous observations that 
reported an excitatory role of BDNF in the gut.  Consistent with these examples ,  recombinant 
methionyl human BDNF (Hr-Met-BDNF) was tried to treat amyotrophic lateral sclerosis and 
diabetic neuropathy in human subjects and the main side effects were increased gut motility, 
diarrhea and increased bowel urgency [45, 46]. In rats, exogenous BDNF can stimulate gut 
myoelectric activities [47]. Presence of BDNF in gut smooth muscle cells has been documented 
in a few studies [41], but no one has characterized the BDNF system in gut smooth muscle cells. 
In addition to the excitatory effect of BDNF on the sensory part of gut motility signaling, it could 
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play an important role in the motor side of the motility reflex. One recent report published since 
start of this thesis project has also found that BDNF enhances the contraction of intestinal muscle 
strips from mice in response to contractile SP and CGRP[48].  
1.1.5.3.b BDNF in diseased gut 
The previous section summarizes the anatomical and physiological observation of BDNF 
in the gut. In addition to these findings in normal animals, BDNF has been described in different 
pathological states of the gastrointestinal tract. One of the main diseases that  affects the gut is 
the inflammatory bowel disease (IBD) which comprises two different diseases, ulcerative colitis 
(UC) and crohn’s disease (CD). Several studies reported differential changes of neurotrophins 
profile during the course of the disease in several animal models of IBD and in human CD and 
UC tissue samples[49]. BDNF has been implemented in several aspects of colitis including the 
induction of the disease and the symptoms accompany it, such as pain. One study demonestrated 
that BDNF immunoreactivty is decreased in UC patients compared to control patients [50].  On 
contrary, Grider et al  showed that  BDNF level increased in several cell types in UC animal 
model. Up regulation of  BDNF in colon tissue  was time and region- specific with the increase 
being most in the muscle layer of proximal colon. The increase of BDNF early in UC correlates 
with the massive neuronal loss that happens early in the disease. The changes of BDNF level 
suggest that BDNF might regulate neuronal loss and recovery during the time course of UC. 
Moreover, BDNF expression in colon was increased in Patients with IBD [51].  Strong evidence 
implemented BDNF in the  inflammation-induced sensory hypersensitivity via modulating the 
sensitivity of primary afferents [52]. Immunoneutralization of BDNF in UC animal models 
significantly reduce the hyperalgesia associated with  the inflammation [53]. On the other hand,  
exogenous BDNF significantly enhances the pain related to inflamed colon. BDNF(+/-) mice 
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showed lower sensitivity in the colon of  UC model compared to BDNF(+/-) mice [51]. These 
studies suggest that BDNF may contribute to visceral hypersensitivity in patients with IBD. 
In addition to its role in IBD, BDNF has an essential role in energy homeostasis and its 
deregulation resulted in eating disorders. BDNF heterozygous mice exhibited  hyperphagia and 
develop an age-dependent obesity [54]. The same phenotype was associated with humans with 
BDNF haploinsufficiency. Intracerebroventricular BDNF infusion resulted in upregulation of 
hypothalamic 5-hydroxyindoleacetic acid/serotonin (5-HIAA/5-HT) ratio, associated with severe 
appetite suppression and weight loss [55]. Moreover, BDNF represent a key molecule that 
governs the proper communications between the gut and the brain. For example, alteration of the 
gut microbiota resulted in increased hippocampal BDNF expression [56]. The gut-brain axis 
provides an explanation how GI tract disordes can influence psychiatric and emotional disorders 
in which BDNF plays a major role [57]. 
 
1.2 Gastrointestinal tract overview 
The gastrointestinal (GI) tract is a complex and cooperative network of numerous organs. 
It fulfills the functions of ingestion and digestion of food, absorption of nutrients, excretion of 
waste and host defense. The muscular tissues in the wall of the tract provide the force necessary 
to transit food from one segment to the next or to stir the contents of the gut for proper digestion, 
absorption. The muscularis layer of the gut wall contains smooth muscle cells that generate 
spontaneous electrical rhythmicity and contractions driven by intrinsic pacemakers. This intrinsic 
electrical activity is generated by neighbouring interstitial cells of cajal (ICC).  Multiple layers of 
regulatory mechanisms working in harmony to produce these highly sophisticated motor 
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patterns. These include, interactions between neurons of enteric nervous system, interstit ial cells, 
and smooth muscle. Hormonal influences and paracrine factors  modulate motor activities during 
normal responses [58]. 
 
1.2.1 Gut anatomy 
 The gut wall is composed of four layers that have structural and functional variations 
along the length of the alimentary canal. The innermost layer is the mucosa which is made up of 
three layers, the epithelium, the lamina propria and the muscularis mucosa. The mucosa is 
responsible for the terminal digestion of the ingested material via secreted brush border enzymes 
and for conveying the absorbed nutrients. Outward radially to the mucosa is the submucosa, 
which is composed of connective tissue, lymphatics, blood vessels and nerve tissues. This layer 
has the submucosal enteric plexus which are also neurons from the autonomic nervous system. 
The third layer is the muscularis propria, which composed of an  inner thick, circular smooth 
muscle and outer thin, longitudinal muscle cell layers. The orientation of the long axis of the 
muscle cells relative to the lumen gives these layers their names. The myenteric nerve plexus 
separates the circular from the longitudinal muscle layers and controls their muscular activity. 
The outermost layer of the gut is the serous membrane; the serosa is composed of connective 
tissue that wraps up the gut tube and protects it from friction with other organs. 
The cellular identity and characteristics vary between of  each layer of the GI tract. The 
main cell types in each layer are discussed here, with emphasis on the muscularis propria and the 
enteric nervous system, which are responsible for the coordinated contractile movements of the 
gut. 
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1.2.2 Cells of the epithelium  
The GI tract contains  a complex, rapidly proliferating and continuously differentiating 
epithelium. The epithelium is distinctly different in various regions of the tract. Several cell types 
contribute to the epithelium, including cells devoted to secretion, production of hormones and 
absorption. In the intestine for example, the epithelium arranged in a structural and functional 
units called the crypts and villi. The stem cells in the crypts are the source of the major 
terminally differentiated  cell types, the absorptive enterocyte, the mucus- secreting goblet cell,  
enteroendocrine cell, and paneth cells. In addition to these main cell types, the epithelium is rich 
in immune and lymphatic cells that make an essential defense barrier against  most pathogens 
[59]. 
1.2.3 Enteric nervous system (ENS) 
The ENS is the second largest accumulation of  neuronal cells in the body, second to the 
brain. The nerve cells of the ENS have cell bodies positioned in two ganglionated plexuses. The 
submucous plexus is located between the circular smooth muscle layer and the connective tissues 
of the innermost submucosal layer. The myenteric plexus lies between the inner circular smooth 
muscle and the outer longitudinal smooth muscle layers throughout the alimentary tract [60]. The 
ENS has several distinct characteristics that enable it to regulate gastrointestinal functions, these 
include, the plurichemical neurotransmission profiles, i.e.  different neurotransmitters coding 
with co-existence of transmitters, the  axonal projections in oral or anal directions, the  full 
repertoire of synaptic transmission, i.e. fast and slow excitatory and inhibitory potentials and the 
pronounced modulation by non-neuronal mediators [61]. 
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1.2.3.1 Classification of ENS neurons 
 Neurons of the ENS can be classified according to morphological, chemical coding, 
electrical and functional criterion. No one classification is sufficient to describe a specific 
neuron. But one neuron should be described using different or all the measures of classification. 
 
1.2.3.1a Morphological and Chemical coding 
Morphologically, enteric neurons are divided on the basis of the different shapes and 
lengths of their dendrites into Dogiel type I to type VII and giant neurons [62]. Type I neurons 
have a single axon and short lamellar dendrites, whereas type II neurons have multiple long 
processes arising from a large smooth cell body [63]. Dogiel type I neurons are characterized by 
a number of electrophysiological and chemical features. In guinea pig, these neurons function as 
motor and interneurons and they  have S electrophysiological properties. On the other hand, 
Dogiel type II neurons are located both in the myentric and submucous plexus. At least in the 
guinea-pig small intestine, type II neurons have the electrophysiological characteristics of AH 
neurons and many of these neurons function as primary afferents [64]. Types III to VII are 
variously described in different species and regions [65].  According to chemical coding ENS 
neurons usually express a combination of different neurotransmitters, such as acetylcholine, 
tachykinins, nitric oxide synthesis, pituitary adynylate cyclase-activating peptide and vasoactive 
intestinal polypeptide. The chemical identity of a neuron depends of the function of that neuron,  
and can identify a neuron with specific morphology or a specific function.  For example, 
excitatory motor neurons are immunoreactive for both the synthesizing enzyme for ACh (choline 
acetyltransferase) and for tachykinins while the inhibitory motor neurons are immunoreactive for 
VIP, PACAP and  nitric oxide synthase (NOS) [62, 66]. 
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1.2.3.1b Electrophysiological classification 
Based on electrical behavior of neurons of the ENS two types of neurons can be 
identified, synaptic (S) and afterhyperpolarization neurons (AH). Synaptic type neurons are 
usually of Dogiel type I neurons, while the afterhyperpolarization type are Dogiel type II.  S/type 
I neurons  are characterized  by having relative low resting membrane potential, higher input 
resistance, repetitive spike discharge, no prolonged hyperpolarizing afterpotentials and 
sensitivity of their somal spikes to tetrodotoxin. On the other hand, AH/ type II neurons are 
distinguished by their high resting membrane potential, lower input resistance than S/type I cells,  
having one or two spike discharge, prolonged afterhyperpolarizing potentials, and tetrodotoxin-
resistant action potentials [67]. 
 
1.2.3.1c Functional classification 
 Finally, ENS neurons are classified functionally into motor neurons, interneurons and 
sensory neurons [68, 69]. Motor neurons are S/type I neurons. They are subdivided into muscle 
motor neurons, secretomotor neurons and neurons innervating entero-endocrine cells. In this 
category, muscle motor neurons innervate the circular and the longitudinal muscle layers and the 
muscularis mucosa.  Motor neurons to each area include excitatory and inhibitory neurons that 
release neurotransmitters to induce contraction and relaxation respectively [70].   Interneurons 
are both synaptic and afterhyperpolarization types and most often Dogiel type I neurons. They 
are subdivided into ascending and descending interneurons. The ascending interneurons  receive 
fast synaptic inputs and form a chain of ascending excitation and also receive nicotinic and slow 
synaptic inputs from enteric afferent neurons. They project orally and synapse with the excitatory 
muscular motor neurons [70]. The descending interneurons are more diverse with mixed 
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chemical coding. They send projections anally to make synapses with the inhibitory motor 
neurons [66]. Sensory neurons are the third class of functional neurons and, they composed of 
dense fibers of extrinsic and  intrinsic primary afferent neurons (IPANs). The extrinsic afferent 
neurons have their cell bodies outside the gut wall (vagal and spinal afferents), whereas the 
IPANs have their cell bodies within the gut wall. They work together and with enteroendocrine 
cells to respond to chemical, mechanical stimuli in the gut lumen [70] and to convey these 
stimuli to other neurons of the ENS. Sensory neurons have a wide range of cell surface receptors 
that are activated via different molecules such as 5 HT  [66].  
 
1.2.4 Interstitial cells of Cajal (ICC) 
ICC were first described in 1889 by Cajal, S.R. as primitive neurons. The finding that 
ICC express the tyrosine kinase receptor (c-Kit) more than hundred years after their discovery, 
allows the mesenchyma to be identified as the origin of ICC [71]. In addition to c-kit expression, 
ICC are characterized by an important ultrastructural features including numerous mitochondria, 
abundant intermediate filaments, few ribosomes, rough and smooth endoplasmic reticula, and a 
very close contacts with nerve varicosities and the formation of many gap junction with each 
other and with smooth muscle cells [72]. 
ICC cells are classified depending on their location in the gut wall to the following 
subtypes, ICC-MY in the myenteric plexus, ICC-IM within the longitudinal and circular 
muscular layers, ICC-DMP in the deep muscularis plexus, ICC-SMP in the submucosal plexus, 
and ICC-SS in the subserosal layer [73]. Depending on their locations ICC have been assigned 
different functions. ICC-MY  are proposed to pace the slow wave and to regulate slow wave 
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propagation in the stomach and intestine, ICC-IM and ICC-SMP have been implicated in 
neurotransmission of neuronal input to muscle cells [74]. 
 
1.2.5 Smooth muscle cells 
Smooth muscle cells are located in the circular and longitudinal muscle layers and in the 
muscularis mucosa layer of the GI tract wall. They are responsible for contractility of the gut to 
perform mixing and propulsion of intaluminal contents, thus enabling efficient digestion of food, 
progressive absorption of nutrients, and evacuation of residues. These functions are controlled by 
the inherent  properties of gut smooth muscle cells, such as the ability to maintain tone and to 
undergo phasic contraction as well as their interaction with nerves and ICC [75]. 
Smooth muscle cells are spindle-shaped with 400 μm length and 5 to 15μm width. 
Compared to other muscle types, smooth muscle cells are distinguished by lack of the visible 
cross-striations. The plasma membrane of smooth muscle cell is characterized by clusters of 
basket-shaped invaginations called caveolae. These caveolae are separated from each other via 
electron-dense structures called dense bands [76]. Contractile filaments and dense bodies fill 
most of the cytoplasm  of smooth muscle cell. Dense bodies connect thin and thick filament in a 
way similar to Z line in skeletal muscle. Smooth muscle cell contains three types of filaments,  
thin actin filaments, thick myosin filaments and intermediate filaments.  Intermediate filaments 
connect dense bodies in the cytoplasm to dense bands on the cell membrane [75]. 
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1.2.6 Peristalsis 
Peristalsis is a distinct involuntary movements of the longitudinal and circular muscles 
that propels ingested food caudally through the GI tract. It was first described by Bayliss and 
Starling back in 1899 as a distinct pattern of movement entirely mediated by the ENS in response 
to a bolus, where contraction is evoked oral to the bolus and a relaxation is evoked  distal to the 
bolus [77].  The peristaltic reflex can be initiated by distention of the gut wall or by mechanical 
and chemical stimulation of the mucosa. The sensory neurons responsible for the muscle stretch-
mediated reflex are extrinsic afferents with their cell bodies in the dorsal root ganglion, and with 
axonal projections to the enteric neurons within the wall of the intestine. The sensory neurons 
activated by mucosal stimulation are wholly intrinsic with cell bodies located in the ENS. Both 
sets of distinct neurons (i.e. stretch and mucosal- activated) converge on the same population of 
enteric motor neurons mediating the peristaltic reflex [78].  
The peristaltic reflex comprises two phases, oral ascending phase during which the 
circular muscle  contracts and the longitudinal muscle relaxes and an aboral descending phase 
during which the circular muscle relaxes and the longitudinal muscle contracts [79]. 
The  plurichemical coding of enteric motor neurons explains the reciprocal phases of the reflex. 
Oral ascending motor neurons are excitatory neurons with Ach, SP and neurokinin A chemical 
coding. Whereas the  caudad descending motor neurons are inhibitory and contain VIP, NO and 
PACAP [80]. 
1.2.7 Smooth muscle contaction 
Activation of actin-activated myosin ATPase and thus initiation of actomyosin cross 
bridge cycle initiates smooth muscle contraction. Phosphorylation of 20-kDa regulatory light 
chain of myosin II (MLC20) on serine residue at position 19 is essential to start the actomyosin 
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cross bridge cycle and thus muscle contraction. Elevation of free intracellular Ca
+2
 level induces 
activation of Ca
2+
/calmodulin dependent MLCK which phosphorylates MLC20 that leads to 
muscle contraction. Muscle contraction and MLC20 phosphorylation is maintained even after the 
decline in intracellular Ca
+2
 level and MLCK activity. MLC20 is phosphorylated by kinases 
other than Ca
+2
 dependent MLCK. Moreover, the phosphorylation level can be maintained by the 
inhibition of myosin light chain phosphatase (MLCP) which is committed to the 
dephosphorylation of MLC20. The balance between MLCK and MLCP governs the 
phosphorylation state of MLC20 and thus muscle tone. Both MLCK and MLCP are under tight 
regulation in smooth muscle cells [81]. 
 
1.2.7a Contraction in circular smooth muscle cells 
In circular smooth muscle cells, binding of agonists to cell surface receptors (e.g., 
muscarinic m3 receptors) induce activation of Gq, which leads to hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP
2
) by activating phospholipase C (PLC)-β1. PIP2 
hydrolysis generates two effector enzymes; the cytoplasmic soluble messenger inositol 1,4,5-
trisphosphate (IP3) and the membrane bound diacylglycerol (DAG).  IP3 binds to its high 
affinity receptors IP3 receptors/Ca2+ channels  on the sarcoplasmic reticulum (SR) and induces 
Ca
+2
 mobilization which eventually causes muscle contraction [82]. 
 
1.2.7b Longitudinal Smooth Muscle Contraction 
In both circular and longitudinal muscle cells the rise in cytosolic Ca
+2 
is the essential 
physiological process for initial contraction and it takes place in response to ligand-receptor 
activation. Longitudinal smooth muscle cells induce the increase in intracellular Ca
+2
 level 
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differently than circular muscle cells. Muscle cells from the longitudinal layer contain a small 
amount of PIP2 and generate little IP3. In addition their SR does not express IP3 receptors/Ca
2+
 
channels but they have ryanodine receptors [83]. Those ryanodine receptors have a high affinity 
for Ca
+2
 and cyclic ADP ribose [84].  Ca
+2
 influx is a necessary step for Ca
+2
 mobilization and 
consequent contraction in longitudinal muscle [82].  Receptors stimulation induce activation of 
cytoplasmic phospholipase A2 (cPLA2), which in turn liberates arachidonic acid from membrane 
lipids. Arachidonic acid activates chloride channels that leads to membrane depolarization which 
opens voltage gated Ca
+2
 channels. Cytosolic Ca
+2
  activates ryanodine receptors and induces 
Ca
+2
  release. Moreover, Ca
+2
  entry  activates cyclic ADP ribose formation which further induce 
more Ca
+2
  through rayanodine channels [85]. All the signaling pathways converge downstream 
of intracellular Ca
+2
  elevation in both muscle layers. 
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SIGNIFICANCE 
 
A great wealth of literature has focused on BDNF in the central and peripheral nervous 
system. It has been reported to play essential roles in neuronal survival, differentiation, 
regulation of neurite growth, synaptic plasticity, synaptic strength, neurotransmitters modulation 
and neuronal phenotypic expression.  In addtion to these well established roles in the nervous 
system, BDNF has a  strong  current therapeutic potential for several  neurological disorders, 
including amyotrophic lateral sclerosis (ALS), depression,  peripheral neuropathy, Parkinson’s 
disease and Alzheimer’s disease. There is a growing understanding of BDNF function outside 
the nervous system. For example, BDNF plays an important role in the immune system, 
cardiovascular system, respiratory system and in the gastrointestinal system. The present project 
is based on an extension of the published and preliminary data from our lab on the function of 
BDNF on the gut. Giving the reported role of BDNF in strengthening the sensory limb of the 
peristaltic reflex, an understanding of the physiological effect of BDNF on all aspects of the gut 
motility especially on gut smooth muscle cells will open new avenues for the discovery of new 
pharmacological agents to treat gut motility disorder and further understanding of the role of 
BDNF in pathological processes such as IBD. A therapeutic agent based on BDNF mechanism 
of action, might induce gut motility physiologically without the  deleterious side effects seen 
with most of the available promotility agents. 
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Hypothesis and specific aims 
 
Based on the established effect of BDNF in the nervous system and results elsewhere in 
the body (airways and gut) along with  preliminary results, the hypothesize is that the 
neuropeptides released from motor neurons act on smooth muscle cells to release BDNF. BDNF 
in return acts in paracrine fashion pre-junctionally to further stimulate the release of 
neuropeptides [86, 87], and acts in autocrine manner to strengthen the effect of neurotransmitters 
on smooth muscle. Altogether, BDNF action in this regard is to enhance the signaling involved 
in smooth muscle contraction and relaxation.   
specific aim 1: To identify the localization of BDNF in intestinal smooth muscle layers and to 
determine its basal expression and secretion in these muscle layers. 
Hypothesis: intestinal smooth muscle cells contribute to gut BDNF pool by being a site of 
synthesis and release of this neurotrophic factor. 
specific aim 2: Identify the secretory pathways, mediators, and the receptors that regulate 
expression and secretion of BDNF from intestinal smooth muscle cells. 
Hypothesis: BDNF is synthesized in activity dependent manner in response to extracellular 
triggers. Gut neuropeptides like SP and PACAP  modulate the synthesis and secretion of BDNF 
in smooth muscle cells.  
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specific aim 3:  To determine the potential role of BDNF in smooth muscle contraction. 
Hypothesis: BDNF as a modulating factor enhances the agonist-induced contraction. These 
agonists include the main contractile agonist, acetylcholine and SP. 
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CHPTER 2 
MATERIALS AND METHODS 
 
2.1 Materials 
Collagenase CLS type II and soybean trypsin inhibitor were obtained from Worthington,  
reehold, NJ; Western blotting, Dowex AG-1 X 8 resin (100-200 mesh in formate form), 
chromatography material and protein assay kit, Tris-HCl Ready Gels were obtained from Bio-
Rad Laboratories, [
3
H]Scopolamine were obtained from PerkinElmer Life Sciences (Boston, 
MA); methoctramine (muscarinic m2 receptor antagonist) and 4-DAMP (muscarinic m3 receptor 
antagonist) Sigma-Aldrich, (St. Louis, MO); U73122 (PLC inhibitor), PD98059 (ERK1/2 
inhibitor) and LY294002 (Akt inhibitor) were obtained from Enzo Life Sciences, Inc., NY; 
Substance P, Bachem Americas, Inc., CA; K252a (TrkB inhibitor) was obtained from 
(Calbiochem, Cambridge, MA) BDNF ligand and ELISA kit were obtained from Promega 
Corporation, WI;  Antibodies: BFNF, GAPDH, TrkB, P75NTR, were obtained from Santa Cruz 
biotechnology, Santa Cruz, CA; RNAqueousTM kit was obtained from Ambion, Austin, TX; 
PCR reagents were obtained from Applied Biosystems, Roche; SuperScriptTM II Reverse  
Transcriptase was obtained from Invitrogen, CA; Dulbecco‟s 25 modified Eagle‟s medium 
(DMEM) was obtained from Fisher Scientific. All other chemicals were obtained from Sigma, 
St. Louis, MO. 
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New Zealand white rabbits (weight: 4-5 lbs) were purchased from RSI Biotechnology, 
Clemmons, NC and killed by injection of euthasol (100 mg/kg), as approved by the Institutional 
Animal Care and Use Committee of the Virginia Commonwealth University. The animals were 
housed in the animal facility administered by the Division of Animal Resources, Virginia 
Commonwealth University. All procedures were conducted in accordance with the Institutional 
Animal Care and Use Committee of the Virginia Commonwealth University. 
 
2.2 Methods: 
2.2.1Tissue collection  
Rabbits were  euthanized by Euthasol injection (100mg/kg body weight) into the ear vein. 
The small intestine was dissected out, emptied of contents, and placed on cold smooth muscle 
buffer (SMB) of the following composition (NaCl 120 mM, KCl 4 mM, KH2PO4 2.6 mM, 
CaCl2 2.0 mM, MgCl2 0. 6 mM, HEPES (N-2-hydroxyethylpiperazine-N‟ 2-ethanesulfonic 
acid) 25 mM, glucose 14 mM, and essential amino mixture 2.1% (pH 7.4) [85-87].  2-3 cm 
sections of the intestine were removed and mounted onto glass rod, the fat and mesenteric 
attachments were removed and the longitudinal muscle was separated from the circular layer by 
radial abrasion with Kime wipe. Intestinal smooth muscle strips handled in this way were used 
for digestion to prepare smooth muscle cultures.  
 
2.2.2 Preparation of dispersed intestinal smooth muscle cells 
Smooth muscle cells from intestinal longitudinal and circular muscle layers were isolated 
by sequential enzymatic digestion of muscle strips, filtration, and centrifugation as described 
previously [88]. Muscle strips were incubated for 15 min at 31°C in 30 ml of smooth muscle 
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buffer containing 0.1% collagenase (type II) and 0.1% soybean trypsin inhibitor. The tissues 
were continuously gassed with 100% oxygen during the whole isolation process. The partly 
digested tissues were washed with 100 ml of enzyme-free smooth muscle buffer and reincubated 
for 10 min to allow spontaneous dispersion of muscle cells. Cells were harvested by filtration 
through 500 μM Nitex mesh and centrifuged twice at 350 g for 10 min. 
 
2.2.3 Preparation of cultured intestinal smooth muscle cells 
  The dispersed smooth muscle cells were resuspended in Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing penicillin (200 U/ml), streptomycin (200 μg/ml), gentamycin (100 
μg/ml), amphotericin B (2.5 μg/ml), and 10% fetal bovine serum (FBS)  (DMEM-10). The 
muscle cells were plated at a concentration of 5 X 10
5
  cells/ml and incubated at 37°C. DMEM-
10 medium was replaced every 3 days for 2–3 wk until confluence was attained. The muscle 
cells in confluent primary cultures were trypsinized (0.5 mg trypsin/ml) to remove them from the 
culture dish, replated at a concentration of 2.5 X 10
5
 cells/ml, and cultured under the same 
conditions. All experiments were done on cells in first and second passage. The purity of the 
cultures were determined by staining with monoclonal antibody HM19/2 for smooth muscle-
specific γ-actin. Cultured smooth muscle cells were starved in serum-free medium (DMEM-0) 
for expression, release and pharmacological treatment experiments. 
Cultured cells were treated with 10 nM and 100 nM of SP or PACAP for 24 hrs and 48 
hrs. For 48 hrs treatment, the medium was changed on the seconed day with fresh SP and 
PACAP to avoid peptides degradation and unwanted cumulative effects. For control 
experiments,  cultures were treated with DMEM-0. After the incubation periods, the cultured 
medium supernatents were collected and stored at -80° for subsequent ELISA experiments to 
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detect BDNF release. The treated cultured cells were collected by two different ways first using  
Triton X-100-based lysis bufer plus protease and phosphotase inhibitors and stored at -80 C˚ for 
subsequent Western blotting or by trypsinization and centrifugation for PCR analysis.  
2.2.4 Preparation of muscle strips 
Intestinal muscle strips designated for tension recording were prepared in the following 
way; the intestine was removed  quickly after sacrificing the animal, and it was cleaned from 
contents and placed in a warmed (37 °C) oxygenated Krebs solution with the following 
constituents (in mM): 118 NaCl, 4.75 KCl, 1.19 KH2PO4, 1.2 MgSO4, 2.54 CaCl2, 25 NaHCO3, 
11 mM glucose (pH 7.4). Segments of whole wall, 2-3 cm long were freed of fat and mesenteric 
attachments. The longitudinal layer was peeled off carefully using wet Kime wipes and held in 
oxygenated Krebs buffer until use for tension recording. 
Muscle strips were tied in the direction of  the longitudinal muscle layer at both ends with 
surgical silk- one end to a simple loop for attachment to a glass hook, the other end to a length of 
silk tied to a brass ring. The strips were then placed in a vertical orientation with the loop secured 
to a glass hook and the brass ring to a Model FT03C Force Transducer (Grass Technologies, 
Quincy, MA).  An organ bath (Radnoti, Monrovia, CA) was raised to submerge the strip in 5 or 2 
mL of continuously oxygenated and warmed Krebs solution.  The bath fluid was changed several 
times during equilibration and several times after each reagent. Force recordings were amplified 
by a 15A12 model amplifier (contained within a Model 15LT Amplifier System), relayed to a 
PVA-16 Polyview Adaptor (Grass Instruments, Quincy, MA). 
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2.2.4.1 Experimental design and data analysis for tension experiments 
The strips were allowed to equilibrate at 1 g tension for at least 1 h before any experiment. 
Exposure to test drugs, inhibitors, carbachol and SP was done in organ bath with concentrations 
determined from  literature and in our preliminary studies and are stated in the results section. 
Each strip served as control for its own treatment. 
Each experiment was conducted in the following manner, two strips were assigned for 
each experimental condition. Control strips were received a first dose of either CCh or SP for 3 
min, then washed a total of 3 times with 15 min interval. A seconed dose of CCh or SP was 
applied after that and a second cycle of 3 times washing was applied. For BDNF-treated strips, 
BDNF was applied following 1 hr equilibration then the strips were exposed to CCh or SP for 3 
min.The strips which assigned for antagonist treatments, the antagonist was added to the bath 15 
min before CCh and BDNF. 
Results were analyzed using the polyview software program, where basal tone was 
measured as the mean tension during a 3 minute period following at least 30 min of equilibration 
(control conditions) or 15 min of inhibitor incubation (basal recording obtained in interval 
proceeding carbachol or BDNF administration). Peak contraction was measured as peak to peak 
(P-P) contraction during the two minute period following agonist administration in grams. These 
numerical values were compared between treatment conditions and controls. The appropriate 
stastistical tests (Paired t-tests or ANOVA test) were carried out in GraphPad (GraphPad 
Software, La Jolla, CA). A probability of p<0.05 was considered significant. Values are reported 
as mean ± SEM.   
 
30 
  
2.2.5 Histology and immunohistochemistry 
Intestinal sections were immunostained using on-slide technique. Smooth muscle cells were 
seeded in slide wells and immunostained. Intestinal samples were obtained directly after sacrifice 
of the animals. 3-5 cm long pieces were cleaned with SMB and placed in 4% paraformaldehyde 
fixative solution overnight at 4
°
. Then, the pieces were moved to 30% sucrose in .1 M PBS 
solution for 1-3 days at 4
°
 and routinely embedded in paraffin. Cross sections (8 mm) were cut 
and mounted on gelatin-coated microscope slides. The slides were warmed at 37
°
 for 1 hr and 
permeabilized with 0.3% Triton X-100 in 0.1 M PBS slousion for 20 min. For cultured cells, the 
slide wells were fixed with 4% paraformaldehyde for 20 min at room tempreasure. Both 
preparations were incubated for 1 h at room temperature  with blocking solution containing  3% 
normal donkey serum (Jackson ImmunoResearch, West Grove, PA) in PBST (0.3% Triton X-
100 in 0.1 M PBS, pH 7.4). The sections then were incubated with primary antibody diluted in 
PBST containing 5% normal donkey serum overnight at 4 °C. For BDNF antibody we used 
BDNF antibody from (Santa Cruz, CA) in 1:500 dilution. After rinsing (3 × 10 min with 0.1 mol 
L) 1 PBS), the sections were incubated with fluorescence- conjugated species-specific secondary 
antibody Alexa 594 for 2 h at  room temperature. The slides then were thoroughly washed and 
covered with Citifluor.  To evaluate for nonspecific binding, we incubated the control sections as 
described above but without the primary antibody. Western blot analysis was carried out to test 
for specificity of the anti body for BDNF.   
 
2.2.6 Protein extraction 
Cultured smooth muscle cells were homogenized with solubilization buffer of the following 
composition, 50 mM Tris-HCL, 150 mM NaCL, 1 mM EDTA, 1% Triton X-100, 100 mM NaF. 
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Protease inhibitor cocktail and phosphatase inhibitor cocktail (100 μg/ml PMSF, 10 μg/ml 
aprotinin, 10 μg/ml leupeptin, 30 mM sodium fluoride and 3 mM sodium vanadate) were added 
to this buffer. After sonication for 15 second and centrifugation at 2000 g for 10 min at 4˚C, the 
protein concentrations in the supernatant was determined using a Dc protein assay kit from Bio-
Rad (a colorimetric assay to detect protein concentration after detergent solubilization based on 
Lowry assay).  
 
2.2.7 Western immonoblotting 
Equal amounts of proteins were separated by SDS/PAGE electrophoresis using 10% and 
15% (w/v) acrylamide resolving gel. The separated proteins were electrophoretically transferred 
onto a nitrocellulose membrane. The membrane was blocked by incubation with 5% (w/v) non-
fat dried milk / TBS-T (tris-buffered saline, pH 7.6 plus 0.1% Tween-20) for 1h at room 
temperature with gentle shaking. Then the membrane was incubated for 25 hr at 4°C with 
different primary antibodies diluted in TBS-T 1% (w/v) non-fat dried milk (Table1).  After 
washing with TBS-T (3×5 min), the membrane was incubated with horseradish-peroxidase- 
conjugated matching secondary antibody (1: 2000) in TBS-T with gentle shaking at room 
temperature for 1h. After the membrane was washed with TBS-T (3×5 min), the immunoreactive 
blot was visualized by SuperSignal Femto maximum sensitivity substrate kit. 
To ensure equal amount of protein loading, in each blot the same membrane was stripped 
and re-blotted against a housekeeping protein such as actin or GAPDH Densitometric 
quantification of protein bands were done using the software FluoroChem 8800. The average 
bands intensity were normalized to that of the control of the same lane. 
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Table 1. Primary antibodies. Primary antibodies and their catalogue number, company of 
production, product size and dilution ratio.   
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Table 1: 
Antibody Catalog # Product size 
(kDA) 
Company 
name 
Dilusion Species  
BDNF (N-20) 12112 14 Santa cruz 1:500 Rabbit 
BDNF AB1513P 14 Millipore 1:500 Sheep 
TrkB (H-181) sc-8316 95-145 Santa cruz 1:1000 Rabbit 
PLC- 1249 sc-81 155 kDa. Santa cruz 1:1000 Rabbit 
P-PLC-(pY783.27) sc-136186 155 kDA Santa cruz 1:1000 Mouse 
P-ERK1/2(137F5) 
 
4695 
 
40/42 kDa Cell signaling 1:1000 Rabbit 
AKT 9272S 60 kDa Cell signaling 1:1000 Rabbit 
P-AKT (Ser473) 
(587F11) 
4051 60 kDa Cell signaling 1:1000 Mouse 
Β-actin AC1978 42 Sigma 1:10000 Mouse 
GAPDH(6C5) G0110 37 Santa Cruz 1:1000 Mouse 
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2.2.8 In-Cell western Assay (ICW Assay) for BDNF protein detection  
ICW assay is a quantitative  immunofluorescence assay that is alternative to classical western 
blotting and ELISA. It was used to examined the intracellular singalling pathways that governs 
BDNF synthesis. ICW is conducted in microplates (96- or 384-well format). The technique is 
composed of the following steps in brief; primary smooth muscle cells were cultured in 96 well 
plates, treated with SP  and/or PACAP or  DMEM 0 alone for 24 hrs. The supernatants were 
aspirated and the cells fixed immediately with Fixing Solution (3.7% formaldehyde in 1X PBS) 
for 20 minutes at room temperature (RT) without shaking. To permeabilize, the cells were 
washed five times with 1X PBS containing 0.1% Triton® X-100 for 5 minutes per wash.150 μL 
of Odyssey® Blocking Buffer was added  to each well to block cells for 1.5 hours at room 
temperature with moderate shaking. 50 μL of Odyssey® Blocking Buffer were added to each 
well designated as control well and 50 μL of the BDNF primary antibody in Odyssey Blocking 
Buffer to the rest of the wells. Incubation with primary antibody was done for 2.5 hours at room 
temperature or overnight at 4°C with gentle agitation. Plates were washed five times with 1X 
PBS + 0.1% Tween® 20 for 5 minutes at RT with gentle shaking. 50 μL of Odyssey secondary 
antibody were added to each well for 1 hour at room temperature with gentle shaking. The plate 
was washed five times with 1X PBS + 0.1% Tween® 20 for 5 minutes  at room temperature 
with moderate shaking. ICW provides advantage over traditional western by  allowing more 
accurate normalization of cell number across the whole plate. The simultaneous staining of cells 
with DRAQ5 and Sapphire700 Stains accounts for the high normalization accuracy. In this 
technique the wells assigned as control only were incubated with Odyssey secondary while the 
rest of wells were incubated with Odyssey secondary and DRAQ5 (1:2000) and Sapphire700 
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(1:1000) staines. The plates were scanned with detection in both 700 and 800 nm channels using 
an Odyssey®. 
2.2.9 Enzyme-linked immunosorbent assay (ELISA) 
  BDNF protein in frozen culture supernatants were measured via a sandwich ELISA using 
the Promega (Promega Corporation,WI) BDNF Emax immunoassay according to the 
manufacturer’s directions. Samples were divided into two groups to determine which group yield 
higher detectable amount of protein. In one group, the samples were first acidified to pH < 3.0 
with 1 N HCL for 15 min and then neutralized to 7.6. Samples in the second group were not 
acidified.  The antibody is specific for BDNF with less than 3% cross reactivity with NGF, NT-3 
and NT-4. The limit for detection of this kit is 4pg/ml and the  range is 4 pg/ml to 500 pg/ml. 
Polystyrene ELISA plates were coated with anti-BDNF mAb (1:1000) by adding 100 μl of the 
antibody to each well and overnight incubation at 4° without shaking. On next day the plate was 
washed vigorously with TBST and blocked by adding 200 μl of Block & Sample 1X Buffer to 
each well using a multichannel pipettor and incubated for one hour at room temperature without 
shaking. 100 μl of BDNF standard or samples was added in duplicate and incubated for two 
hours at room temperature. The plate was washed five times and 100 μl anti-Human BDNF pAb 
(1:500) were added to each well and incubated at room temperature for one hour. After five 
times washing of the plate with TBST,  100μl of diluted Anti-IgY HRP Conjugate (1:200) were 
added to each well and the plate incubated for another one hour at room temperature with 
shaking. Then the plate was washed five times and 100μl of room-temperature TMB One 
Solution was added to each well  using a multichannel pipettor and incubated for 10 minutes 
with shaking. 100μl of 1N hydrochloric acid were added to wells in the same order in which 
substrate was added to stop the reaction. The plate was scanned using a plate reader to the record 
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the absorbance at 450 nm with 30 minutes of stopping the reaction.  Concentrations in the 
samples was calculated from the standard curve  
 
2.2.10 RT-PCR 
 
Total RNA from cultured smooth muscle cells was extracted using 
Ultraspec™ RNA isolation kit. To eliminate DNA contamination total RNA was further treated 
with TURBO DNase in the presence with RNase inhibitor. 1 μg of the total RNA was reversely 
transcribed by SuperScript™ II containing 50 mM Tris-HCL, 75 mM KCL, 3 mM MgCl2, 10 
mM dithiothreitol, .5 mM deoxynucleoside triphosphates, 2.5 μM random hexamers and 200 
units of reverse transcriptase in a 20 ul reaction volume.  Quantitative real-time PCR was  
performed for BDNF with a Taqman probe mixed with PCR Master-Mix for 40 cycles (95 C˚ for 
15 sec, 60 C˚ for 1 min) on a 7300 real-time PCR system (Applied Biosystems, Foster City, CA, 
USA). Quantitative real-time PCR of the same sample was performed for β-actin or GAPDH 
expression as internal control for normalization. Primers sequences are included in table 2. 
Reactions for real time PCR were done in triplicate. Only one PCR product was 
generated by each primer set.  StepOne™ Real-Time PCR System software was used to calculate 
the fluorescent threshold value. The possibility of  primer- dimer formation was excluded by the 
lack of peak signal in control wells containing water. 
Quantification of gene expression was done using the relative qRT-PCR  method. The 
signal of BDNF transcript in a treatment group was related to that of the control group. To 
calculate the relative  expression ratio, delta delta CT values were used. CT value is the cycle 
number at which the fluorescence generated within a reaction crosses the threshold.  In this 
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model, the target gene expression is normalized to the expression of non-regulated housekeeping 
genes (i.e. the expression of this housekeeping gene is not affected by the treatment) [89, 90].  
     
 
Delta delta CT method  
ΔΔCT = (C
T, Tag 
− C
T, HKG
) 
Treatment 
− (C
T, Tag 
– C
T, HKG
) 
Control  
R = 2 
−ΔΔCT 
 
Where, HKG is the housekeeping gene and Tag, the evaluated gene.  
GAPDH was selected as housekeeping gene . After normalization BDNF mRNA in response to 
SP treatment was expressed as fold-change in mRNA expression relative to that obtained from 
control samples. 
 
2.2.11 Radioligand binding assay 
Cultured longitudinal smooth muscle cells were divided into a control group and BDNF-
treated group, (10 nM BDNF for 24 hours) and radioligand binding assays were conducted using 
[
3
H] scopolamine [91]. Muscle cells were collected at room temperature using PBS having 10 
μM EDTA and centrifuged for 10 min at 350 x g. Muscle cells were resuspended in HEPES 
buffer (pH 7.4) including 1% fetal bovine serum.  For total binding, triplicate aliquots (0.5 ml) of 
cell suspension (106 cells/ml) were incubated for 15 min with 1 nM [3H]scopolamine. For total 
M3 or M2 receptor binding the cell aliquots were incubated with 1 nM [3H] scopolamine in the 
presence of methoctramine or 4-DAMP respectively. For non-specific binding, excess of 
acetylcholine was added to the aliquots. Unbounded [3H] scopolamine and acetylcholine were 
washed thoroughly by rapid filtration under reduced pressure through 5-μm polycarbonate 
Nucleopore filters followed  by washing the filters four times with 3 ml of ice-cold HEPES 
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buffer containing 0.2% bovine serum albumin. To calculate the specific binding the value of 
non-specific binding was subtracted from that of total binding.  
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Table 2. Real-time and RT-PCR primer sequences. Primers for amplification of different 
genes from smooth muscle tissue. Β-actin, GAPDH; Glyceraldehyde 3-phosphate 
dehydrogenase, BDNF; Brain- derived neurotrophic factor. 
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Table 2: 
Primer 
set  
Forward 5’  3’ Reverse 3’  5’ Size 
(bp) 
Β-actin CCCTCCATCGTGCACCGCAA CTCGTCTCGTTTCTGCGCCGT 100 
GAPDH GCCTGGAGAAAGCTGCTAAGTATG  CCTCGGATGCCTGCTTCA 60 
BDNF TATGAGGGTCGGGCGCCACT TCCCGCCCGACATGTCCACT 20 
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CHAPTER 3 
RESULTS 
 
3.1 Localization of BDNF in intestinal smooth muscle layers 
3.1.1 BDNF Immunohistochemistry 
We used rabbit anti-BDNF polyclonal antibody (SC546; rabbit; 1:500; red) to study the 
immunohistochemical localization of BDNF in the intestine. In normal mice tissue, BDNF was 
present in different intestinal layers (mucosa, submucosa and the muscular tissue) (Fig. 1). 
Interestingly, BDNF staining was more intense in the outer longitudinal muscular layer, whereas 
the inner circular muscle layer was much less immunostained for BDNF. Similar results were 
obtained in sections of rabbit and human intestine (data not shown).  This suggests that the 
intestinal longitudinal smooth muscle cells (SMCs) could physiologically contribute to the pool 
of BDNF in the GI tract. 
BDNF localization in longitudinal SMCs was confirmed using rabbit primary SMCs 
cultures. Specific BDNF staining was detected in cultured longitudinal SMCs cultures stained 
with BDNF antibody produced in sheep (1:400 dilutions) (Fig.2).  
 
 3.1.2 Western blot analysis of BDNF 
To further confirm the immunohistological BDNF findings, western blot analysis of 
BDNF was done on total protein extracts from both rabbit longitudinal and circular muscle layer.  
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Using both rabbit and sheep polyclonal anti BDNF antibodies, we detected specific 
immunoreactive bands corresponding to the correct molecular weight of mature BDNF (14 
kDA). The expression of BDNF protein was detected in both longitudinal and circular muscle 
layer (Fig.3A). Comparing the densities of protein bands in the two regions revealed a 
significantly higher expression of BDNF in longitudinal compared to circular muscle layer 
(longitudinal is 2.7-fold higher than circular layer, p< 0.001, n=8) (Fig.3B). These results are 
consistent with the intense immunostaining of BDNF in the longitudinal muscle layer (Fig1). 
Moreover, western blot analysis of cell lysates from primary longitudinal smooth muscle 
cells (SMCs) demonstrated basal expression of BDNF protein (Fig.5, 6, 7 &8). Another layer of 
verification of the presence of BDNF in longitudinal SMCs was the detection of BDNF using the 
high sensitive imaging technique, In Cell Western (Fig. 14). 
 
3.1.3 qRT-PCR measurement of BDNF gene expression 
Total RNA isolated from longitudinal and circular muscle layer was converted to cDNA 
and subjected to amplification with specific primers for BDNF and GAPDH.  Quantitative real-
time polymerase chain reaction (qRT-PCR) was used to measure RNA levels of BDNF and 
GAPDH was used as internal control.  Consistent with the protein level detected by western blot 
(Fig.2), BDNF mRNA was expressed in both muscle layers and the expression was significantly 
higher (two fold) in the longitudinal compared to the circular layer, p<0.01, n=5) (Fig.4).  
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Figure 1: Selective expression of BDNF in longitudinal muscle layer. 
Immunohistochemical staining of BDNF demonstrated higher levels in longitudinal muscle 
layer.  Middle panel 2; mouse intestine co-stained with antibody to BDNF (SC546; rabbit;1:500; 
red) and serotonin (Immunostar20079; goat; 1:400; green) (100X magnification).  Right panel 3: 
mouse intestine stained with same BDNF antibody; magnification 200X.  Similar results were 
obtained in sections of rabbit and human intestine (data not shown).  No staining was noted in 
the absence of the primary antibody (Left panel1). 
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Figure 1: 
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Figure 2: Primary cultures of rabbit intestinal SMCs showing selective BDNF staining. 
Upper left panel, rabbit SMS stained with Alexa Fluor® 488 Donkey Anti-Sheep antibody alone 
serves as negative control (200X magnification). Upper right panel, rabbit SMCs stained with 
BDNF antibody (sheep; 1:400). Lower panel left and right are the same as upper panel but with 
higher magnification (400X magnification). Bar 200 μm. 
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Figure 2  
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Figure 3: BDNF expression is more in the longitudinal muscle than the circular muscle 
layer. 
(A) Representative western blot of BDNF protein in rabbit intestine tunica muscularis 
(longitudinal (RBL) versus circular(RBC)), β-actin was used as loading control. (B) 
Densitometric analysis of the western blot of BDNF. Relative abundance of BDNF compared 
with β-actin. **P< 0.05. 
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Figure 3: 
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 Figure 4: Quantitative real-time polymerase chain reaction (qRT-PCR) was used to 
measure mRNA levels of BDNF in longitudinal versus circular intestinal muscle layer. 
BDNF mRNA expression is higher in longitudinal compared to circular muscle layer. Data 
were compared based on GAPDH amplification and expressed as fold change (longitudinal 1 
versus circular .57 ± .09), P value = 0.01, n=5. 
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 Figure 4 
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3.2 Modulators of BDNF in Longitudinal Smooth Muscle Cells (SMCs) 
There are many endocrine, paracrine and neurotransmitter agents that might modulate 
expression and release of BDNF from intestinal smooth muscle cells. I will focus on those agents 
with known physiological link to BDNF such as Pituitary Adenylate Cyclase Activating Peptide 
(PACAP) and sunstance P (SP). PACAP and SP are among the main relaxant and contractile 
neuropeptides respectively released from neurons that innervate smooth muscle cells. Several 
reports have documented the strong interplay between those two neuropeptides and BDNF 
synthesis and release elsewhere in the body [35, 92, 93] however when these studies were begun 
there was no evidence for BDNF in gut smooth muscle or changes in BDNF levels in response to 
SP ro PACAP. 
 
3.2.1 Effect of PACAP-38 on BDNF Expression in Primary longitudinal muscle cells 
 
The effect of PACAP on BDNF protein level in primary smooth muscle cells was 
evaluated after 24 and 48 hrs incubation. Longitudinal smooth muscle cells were treated with 
PACAP-38 (10 & 100 nM) for 24 and 48 hrs. PACAP exists in two forms: the full 38 amino acid 
form PACAP-38, and a truncated C-terminal form PACAP-27.  Since both produce identical 
effects, the full form PACAP-38 was used.  Hereafter, PACAP will be used to indicate PACAP-
38 After treatment, total protein was extracted and western blot analysis for BDNF was 
performed. Both doses of PACAP significantly up-regulated BDNF protein expression following 
24 hrs incubation (Fig. 5A). 10 & 100 nM PACAP almost doubled the BDNF protein content in 
primary smooth muscle cells but there was no significant difference in the amount of BDNF 
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induced by the two doses ( bands densities of control: 522±38; 10 nM PACAP:1061±77: 100 nM 
PACAP: 978± 36 respectively, P< 0.001, n=7 (Fig. 5B)). 
PACAP (10 & 100 nM) after 48 hrs incubation increased BDNF protein content (Fig. 
6A). Again, PACAP 100 nM did not produce any further significant difference in BDNF content 
above that induced by 10 nM PACAP. Comparing the densities of protein bands in control, 
PACAP 10 and 100 nM demonstrated that PACAP 10 nM for 48 hrs incubation is the optimal 
dose and time for BDNF up-regulation (Fig. 6B, P< 0.0001, n=6). 
 
3.2.2 Effect of substance P (SP) on BDNF Expression in Primary longitudinal muscle cells 
 
Western blot analysis of primary longitudinal SMC for BDNF revealed baseline 
existence of BDNF. 24 hrs treatment with (10 & 100 nM) SP significantly augmented the level 
of BDNF (Fig. 7) (P=0.005, n=5). 10 & 100 nM showed no significant difference in the ability to 
increase BDNF level after 24hrs incubation, indicating that 10nM SP could be the dose that gives 
the maximal response. 
48 hrs exposure to SP (10&100 nM) demonstrated significantly increased BDNF level in 
primary SMC (P< 0.0001, n=5) (Fig. 8). As in 24 hrs incubation, SP 10nM gave the best 
response. Comparing the band densities of 24 and 48 hrs treatments showed no significant 
difference in BDNF level.   
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Figure 5: 24 hrs PACAP induces upregulation of BDNF protein. 
 Western blot analysis of BDNF was performed on SMC lysates after 24 hrs treatment with 
PACAP 10 & 100 nM. (A) Representative western blot of BDNF (14 kDa) and B-actin (44kDa) 
in SMS, control versus PACAP-treated cells. (B) Summary graph showing the density of western 
bands as determined by the densitometry. Data are expressed as mean values ±SEM, n=7.  
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Figure5:
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 Figure 6: PACAP induces upregulation of BDNF protein content in SMC after 48 h 
treatment. 
Western blot analysis of BDNF was performed on SMC lysates after 48 hrs treatment with 
PACAP 10 & 100 nM. (A) Representative western blot of BDNF (14 kDa) and B-actin (44kDa) 
in SMS, control versus PACAP-treated cells. (B) Summary graph showing the density of western 
bands as determined by the densitometry. Data are expressed as mean values ±SEM, n=6.  
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Figure 6:  
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Figure 7: SP induced upregulation of BDNF protein content in SMC after 24 h treatment. 
Western blot analysis of BDNF was performed on SMC lysates after 24 hrs treatment with SP 10 
& 100 nM. (A) Representative western blot of BDNF (14 kDa) and B-actin (44kDa) in SMS, 
control versus SP-treated cells. (B) Summary graph showing the density of western bands as 
determined by the densitometry. Data are expressed as mean values ±SEM, n=5.  
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 Figure 7: 
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Figure 8: SP induced upregulation of BDNF protein content in SMC following 48 hrs 
treatment. 
Western blot analysis of BDNF was performed on SMC lysates after 48 hrs treatment with SP 10 
& 100 nM. (A) Representative western blot of BDNF (14 kDa) and B-actin (44kDa) in SMS, 
control versus SP-treated cells. (B) Summary graph showing the density of western bands as 
determined by the densitometry. Data are expressed as mean values ±SEM, n=6.  
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Figure 8:  
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3.3 Longitudinal Smooth Muscle Cells Secrete BDNF  
3.3.1 Longitudinal SMCs Constitutively Secrete BDNF 
To evaluate whether longitudinal SMCs at rest can secrete BDNF, primary SMCs were 
cultured for 24 and 48 hrs. The BDNF secretion to the supernatants of SMCs was examined 
using ELISA. We observed a very low constitutive BDNF secretion (in DMEM-0) that was in 
the lower limit of the ELISA kit detection range (Fig.9, 10, 11&12). 
 
3.3.2 Stimulation of Longitudinal SMCs with PACAP and SP  
BDNF is mainly secreted in the regulated pathway of secretion. Extracellular stimulating 
agent is necessary for BDNF regulated secretion [94, 95]. The regulated secretion of BDNF 
depends of the generation of second messengers, mainly, Ca
+2
 and cyclic adenosine 
monophosphate (cAMP) in other tissues [96, 97]. In order to identify the mediators which 
regulate BDNF secretion in longitudinal SMCs, we tested the impact of the neuropeptides 
typically involved in BDNF secretion in neuronal tissues and  which have functional roles in 
intestinal smooth muscle. These neuropeptides tested were PACAP and SP.  
Pituitary adenylate cyclase-activating polypeptide (PACAP) belongs to a family of 
peptides that include vasoactive intestinal peptide (VIP), secretin, glucagon and growth 
hormone-releasing hormone. PACAP binds to three receptors, PAC1-R, VPAC1-R and VPAC2-
R [98]. PACAP is known to activate several intracellular pathways including the cAMP, cGMP 
and the Calcium Induced Calcium Release (CICR) pathway [99]. PACAP controls the synthesis 
and release of BDNF in primary cultures of cortical neurons and astrocytes [92, 100]. In this 
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section, we tested the effect of PACAP on BDNF secretion in primary cultures of longitudinal 
SMCs. 
3.3.2.1 The effect of PACAP on BDNF secretion in longitudinal SMCs 
To study the effect of PACAP on the secretion of BDNF, primary longitudinal SMCs 
cultures were treated with PACAP (10 & 100 nM) for 24 and 48 hrs. The quantity of BDNF in 
the supernatants then was determined by commercially available ELISA kit. PACAP (10 & 100 
nM) incubation for 24 hrs significantly increase BDNF secretion (P<0.05, n=6) (Fig. 9). 10 nM 
PACAP induced the maximal response and there was no further increase in BDNF with PACAP 
100 nM. 48 hrs incubation with PACAP (10 & 100 nM) induced significant increase in BDNF 
release (P<0.05, n=4) (Fig. 10). Comparing the release finding from 24 hrs and 48 hrs PACAP 
treatment showed that 24 hrs with 10 nM PACAP was the dose and time that induce maximal 
BDNF release (15.5 ± 1.4  pg/ml versus 11.9 ± 1.2 pg/ml) (Fig. 9 & 10).  
3.3.2.2 The effect of SP on BDNF secretion in longitudinal SMCs 
Substance P (SP) is a member of the tachykinin family of neuropeptides. In addition to 
SP, this family include, neurokinin A (NKA) and neurokinin B (NKB) which interact with three 
GPCRs designated NK1, NK2 or NK3 receptor [101]. In smooth muscle cells SP is capable  of 
activating PLC and the subsequent elevation of intracellular Ca
+2
. 
To test ability of SP to induce BDNF secretion cultured primary longitudinal SMCs were 
incubated with SP (10 & 100 nM) for 24 and 48 hrs. The cultured medium was then collected 
and BDNF level was quantified by ELISA. 24 hrs incubation with SP significantly augmented 
the release of BDNF (Fig. 11), (6.1± .4 pg/ml control to 11.4±1 pg/ml 10 nM SP, P<0.05, n=5). 
High dose of SP (100 nM) did not produce any further secretion (Fig. 11). 48 hrs treatment with 
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SP induced significant increase of BDNF secretion but it was lower than that induced by 24 hrs 
(Fig.11 &12). 
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Figure 9: BDNF Release from cultured intestinal smooth muscle cells by PACAP 
 Quantitative determination of BDNF release from cultured intestinal smooth muscle cells using 
ELISA. 24 hrs incubation with PACAP 10&100 nM increased BDNF release.  Data are mean 
values ± SEM from at least three animals, asterisks represent significance of at least P<.05. 
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Figure 9: 
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Figure 10: BDNF Release from cultured intestinal smooth muscle cells by 48 hrs treatment 
with PACAP. 
 Quantitative determination of BDNF release from cultured intestinal smooth muscle cells using 
ELISA. 48 hrs incubation with PACAP 10&100 nM increased BDNF release.  DATA are mean 
values ± SEM from at least three animals, Asterisks represent significance of at least P<.05. 
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Figure 10: 
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Figure 11: BDNF release from cultured intestinal smooth muscle cells (24 hrs SP 
stimulation) 
SP induces BDNF release from cultured SMC. Primary SMC were treated with 10 and 100 nM 
SP for 24 h and the cultured medium was subjected to ELISA analysis for BDNF. Data 
expressed as mean values ± SEM of at least three different experiments.*P<0.05. 
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Figure 12: BDNF Release from cultured intestinal smooth muscle cells (48 hrs SP 
stimulation) 
SP induces BDNF release from cultured SMC. Primary SMC were treated with 10 and 100 nM 
SP for 48 h and the cultured medium was subjected to ELISA analysis for BDNF. Data 
expressed as mean values ± SEM of at least three different experiments. *P<0.05. 
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Figure 12: 
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3.4 Role of Calcium (Ca
+2
) in the Effect of SP on BDNF in Longitudinal SMCs 
3.4.1 SP-induced BDNF protein expression proceeds through intracellular Ca
+2
 elevation 
Since there are many more SP/Ach containing neurons innervating the longitudinal 
muscle layer that there are PACAP containing neurons, the SP-induced BDNF release was 
studied further. In order to elucidate the signal transduction pathway involved in SP-induced 
BDNF expression, we tested the role of intracellular Ca
+2
, which is the main second messenger 
downstream of SP activation of its neurokinin receptors. Western blot analysis with BDNF 
antibody was demonstrated that blockade of Ca
2+
 signaling by the addition of 1 µM 1.2-bis-(O-
aminophenoxy)-ethane-N,N,N¢,N¢-tetraacetic acid (BAPTA-AM) to chelate intracellular 
calcium. In primary SMCs cultures treated with SP 10 nM for 24 hrs, BAPTA-AM totally 
abolished SP-induced BDNF expression (Fig. 13). 
The role of Ca
+2
 in SP-induced BDNF expression was further confirmed by in cell 
western (ICW) assay (Fig. 14). Addition of 1 µM BAPTA-AM to SMCs cultures treated with SP 
at 10 nM for 24 hrs completely inhibited the upregulation of BDNF protein induced by SP. 
These results demonstrate the importance of intracellular Ca
+2
 elevation for SP to stimulate 
BDNF in rabbit intestinal longitudinal SMCs. 
 
3.4.2 Intracellular Ca
+2
 Elevation is Essential for SP-induced BDNF Secretion 
A hallmark of BDNF regulated secretion is the dependence on increase in intracellular 
Ca
+2
 level. The surge in intracellular Ca
+2
 level could be due to Ca
+2
 influx or mobilization from 
internal stores depending on the cell type. It is worth noting that the increase in intracellular 
calcium in smooth muscle cells derived from the circular muscle layer is from internal stores 
whereas in smooth muscle cells derived from longitudinal muscle it is from influx.  BAPTA-AM 
73 
  
is a high affinity calcium chelator and is capable to eliminate Ca
+2
 regardless of its source. We 
used BAPTA-AM to assess the role of Ca
+2
 in SP-induced BDNF release just as we did above 
for BDNF expression. Consistent with the previous results, SP (10 nM) for 24 hrs significantly 
increased BDNF release. Addition of BAPTA-AM to primary SMCs cultures incubated with SP 
(10nM) for 24 hrs caused BDNF secretion to return to near its control level (Fig.15). 
 
3.4.3 Effect of SP on BDNF mRNA expression 
The effect of SP on BDNF gene expression was evaluated by treating primary SMCs 
cultures with 10nM BDNF for 24hrs. Quantitative RT-PCR demonstrated that, compared with 
untreated control, SP at the indicated dose significantly upregulated BDNF mRNA expression by 
1.5 times (Fig. 16). Next, we examined the role Ca
+2 
in SP-induced BDNF mRNA upregulation. 
Addition of BAPTA-AM to SMCs treated with SP at 10 nM for 24hrs totally abolished SP-
induced BDNF mRNA expression (Fig. 16). 
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Figure 13: SP-induced BDNF expression in intestinal smooth muscle cells (SMC) is 
dependent on intracellular Ca
2+
 elevation determined by standard Western blot.  
Upper panel: representative western blot of SMC lysates showing upregulation of BDNF level 
by 24 h treatment with10 nM SP. 1 µM BAPTA-AM abolished the effect of SP.  Lower panel: 
Densitometry analysis of western blots for BDNF indicating that SP 10 nM significantly 
increased BDNF protein level. BAPTA-Am completely abolished the effect of SP on BDNF 
level. Values represent the mean ± SEM, *P<.05, n=3. 
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Figure 13: 
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Figure 14: SP-induced BDNF expression in intestinal smooth muscle cells (SMCs) is 
dependent on intracellular Ca
2+
 elevation determined by in cell western. 
 In-cell western were performed on cells treated for 24 hours with either 10 nM SP alone or with 
1 µM BABTA-AM .Values represent the mean ± SEM, n=3. Values were normalized to account 
for differences in cell number from well to well by staining with non-specific dyes (sapphire 700 
& DRAQ5). Asterisks represent significance of at least P<0.05. 
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Figure 14: 
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Figure 15: BAPTA-AM inhibits SP-induced BDNF secretion in cultured intestinal smooth 
muscle cells.  
Cells were treated for 24 hours with either 10 nM SP alone or with BAPTA-AM versus DMEM-
0 alone. Values represent the mean ± SEM, n=3. Asterisks are significance of at least P<0.05 
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Figure 15: 
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Figure 16: Induction of BDNF mRNA by SP is blocked by chelating intracellular Ca
2+ 
in 
cultured intestinal smooth muscle. 
 Cells were stimulated with 10 nM  SP  in the presence and absence of 1uM BAPTA-AM for 24 
hours. Total RNA was extracted and reverse-transcribed. Transcript levels were measured by 
qRT-PCR. Values represent the mean ± SEM, n=3. 
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Figure 16: 
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3.5 The role of BDNF in agonists- induced contraction of rabbit longitudinal muscle strips  
To determine if there is a functional effect of the increase in BDNF in longitudinal 
smooth muscle, the effect of BDNF on rabbit LM strips contraction induced by carbachol and SP 
was investigated. First, the contraction induced by carbachol and SP was verified in LM strips 
from rabbit intestine. Second, the strips were incubated with 10 nM BDNF and the changes of 
CCh and SP-induced contraction were investigated. Third, the role of TrkB and the signaling 
pathways downstream of its activation were tested using selective pharmacological inhibitors 
and molecular assays to measure those signaling molecules. 
3.5.1 Carbachol Induces Concentration-Dependent Contraction  
In rabbit intestinal LM, carbachol caused dose-dependent contraction (100 nM-100 μM) 
(Fig. 17). The cumulative contractile responses were .84 ± .07 grams at 100 nM, 1.1 ± .08 grams 
at 1 μM, 1.4 ± .09 grams at 10 μM, 1.5 ± .08 grams at 100 μM (P<.05, n=33). Data represent 
mean values ± SEM.  
3.5.2 Effect of BDNF on Basal Tone 
Exogenous BDNF did not significantly change basal tone following 1hr incubation. 
Administration of 10 nM BDNF alone resulted in no significant change in basal tone from 0.82 ± 
0.025 grams to 0.92 ± .035 grams, P>0.05, n=at least 18, summary of the data is depicted in 
figure 18. 
3.5.3 Effect of BDNF on peak contraction induced by Carbachol 
CCh at 10 μM was used to test the effect of all agents and inhibitors on CCh-induced 
contraction. Contraction after test agent administration was compared to 10 μM CCh peak 
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contraction and values were expressed as percentage. Incubation of rabbit LM strips with 10 nM 
BDNF for 1hr significantly enhanced the contraction induced by 10 μM CCh (Fig.20). The 
contraction of LM was increased by 188% ± 5.9% after pretreatment with BDNF, n=7,  P< 
0.001. LM contraction induced by 10  μM CCh did not changed after 1 hr incubation with Krebs 
buffer only (the control Strip), Initial 1.51 ± 0.156 g versus after 1hr 1.56 ± 0.15 g, n=15, P>0.05 
(fig. 19). 
 3.5.4 Effects of BDNF on contraction of LM strips induced by SP 
SP caused contraction of rabbit LM in dose dependent manner (10 nM to 1 μM), (data not 
shown). Contraction of LM induced by 1 uM SP after 10 nM BDNF pretreatment for 1 hr was 
compared to that induced by 1 μM SP before incubation. 10 nM BDNF incubation for 1 hr did 
not  enhance the contraction induced by 1 μM SP. The recorded change in tension was changed 
from 1 ± 0.07 gram to 1.1 ± 0.1 gram, P>0.05 (Fig. 21) 
 
 
 
 
 
 
 
 
 
 
 
84 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Control contractile response to carbachol. 
CCh induces a dose-dependent contraction of rabbit LM strips. (A) Representative Dose-
response curve to CCh (10
-7
 -10
-4
 M). (B) CCh induces contraction of rabbit LM in dose 
dependent manner. Summary graph of all responses, Data are expressed as mean values ± SEM, 
n=33. 
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Figure 17 
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Figure 18: Effect of BDNF on Basal Tone  
Representative trace showing the effect of 10 nM BDNF administration on basal tone recorded 
from polyview (upper panel). Incubation of the strips with 10 nM BDNF for 1 hr resulted in no 
significant change of basal tone (.82 ±0.025 grams to .92 ± .03 grams, n= 16). Data summary are 
shown in lower panel as mean ± SEM. 
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Figure 18 
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Figure19: Contractions of Repeated Measurements. 
Repeated peak recorded tension in strips was the same in response to CCh 10 µM. Initial 1.51 ± 
0.156 g versus 1.56 ± 0.15 g, n=15. No significance noted. 
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Figure 19: 
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Figure 20: Effect of BDNF on CCh-induced contraction 
(A)Upper panel, representative traces indicate 10 uM CCh-induce contraction was unchanged by 
incubation. The strip was treated with 10 µM CCh (left), washed three times and incubated for 1 
hours and then 10 uM CCh was repeated (right panel).  Lower panel, representative traces 
indicate 10uM CCh-induce contraction before and after incubation with 10nM BDNF for one 
hour. (C) Summary graph shows that BDNF pretreatment significantly increase the contraction 
induced by 10 uM BDNF. Values are means ± SEM percent of CCh-induced contraction, n=7, 
***p<0.001. 
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Figure 20: 
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Figure 21: Effect of BDNF on intestinal LM strips contraction induced by SP 
Incubation of LM strips for 1 hr with 10 µM of BDNF did not significantly change the 
contraction induced by 1 µM SP.  Data are mean values ± SEM, n=7. 
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Figure 21: 
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3.6 Effect of TrkB inhibition on BDNF enhancement of CCh-induced contraction 
The physiological effect of BDNF is mediated by two cell surface receptors, TrkB and 
P75NTR. Both receptors are expressed by longitudinal SMCs. Therefore, the effect of BDNF on 
cholinergic-induced contraction could be attributed to either or both receptors. To test the role of 
TrkB, we used K252a, an agent that selectively inhibits Trk kinase activity [102], which totally 
abolished the enhancement of CCh-induced contraction due to BDNF pretreatment in this study 
(Fig. 22). 
3.6.1 Effect of TrkB inhibition on CCh peak contraction 
Blockade of TrkB with K252a (1 µM)  had no significant effect on  peak contraction of 
10μM CCh. Peak contraction following K252a incubation for 1 hr was 19% ± 8% lower than 
control peak contraction, but that reduction was not statistically significant, P>0.05 (Fig. 22). 
3.6.2 Effect of TrkB inhibition on BDNF enhanced CCh-induced contraction 
Administration of 1 µM K252a 15 min before BDNF exposure markedly prevented 
BDNF-induced enhancement of contraction due to 10 μM of carbachol (Fig.22). Peak 
contraction following TrkB inhibition in the presence of BDNF was similar to control peak 
contraction of CCh alone. (P >0.05 between control contraction and contraction after K252a and 
BDNF)  
3.6.3 Effect of TrkB activation on carbachol peak contraction  
Trk B activation via two specific Trk B agonists significantly increased contraction by carbachol 
to a level similar to that seen by BDNF (Fig. 23). Administration of LM 22A4 and 7,8-
Dihydroxyflavone 60 min before challenging with carbachol enhanced the contraction by 78% 
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and 61% respectively, P<0.05 (Fig. 23). These data indicate that the effect of BDNF is mediated 
through activation of TrkB, even though we cannot exclude the contribution of P75NTR 
activation since no selective P75NTR antagonists exists at the time these studies were done. 
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Figure 22: Role of TrkB in BDNF mediated enhancement of intestinal LM contraction 
induced by CCh.  
1 uM K252a for 15 min did not significantly affect the contraction induced by 10 uM CCh. 
Incubation of LM strips with 10 nM of BDNF resulted in significant augmentation of contraction 
induced by 10 uM CCh.  BDNF resulted in 88% increase in contraction relative to CCh alone.  1 
uM K252a for 15 min before BDNF introduction resulted in a contraction that was not 
significantly different from that elicited by 10 uM CCh alone.  Data represent the percent of 
contraction relative to CCh. Values denote means ± SEM from at least three animals. **P < .005. 
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Figure 22:   
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Figure 23: TrkB activation by selective agonists enhances the contraction induced by CCh. 
Activation of TrkB with selective synthetic agonists led to significant increase in contraction 
induced by 10 µM CCh. Application of 1 µM of either LM 22A4 or 7, 8-Dihydroxyflavone for 
60 min augmented CCh induceded contraction. Data represent percentage of control CCH 
contraction.*P<0.05, n=6. 
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3.7 The signaling pathways involved in the effect of BDNF on carbachol-induced 
contraction 
In general, at least three signaling pathways (MAPK, PLC-γ and PI3K) are responsible 
for BDNF mediated signal transduction in a variety of tissues [103]. To deduce the signaling 
pathways involved in BDNF effect on cholinergic-induced contraction in rabbit LM, we used 
pharmacological inhibitors to block the key enzymes in these pathways in intestinal LM strips. 
Furthermore, we measured the level of activated enzymes in response to BDNF in muscle strips 
utilizing specific antibodies to these enzymes. 
 
3.7.1 Effect of MAPK inhibition 
Incubation of LM strips with 10 μM PD98059 (an ERK1/2 specific inhibitor) for 15 min 
was used to assess the role of MAPK in BDNF effect of CCh-induced contraction. ERK1/2 
inhibition was tested in respect to basal tone, CCh peak contraction and CCh peak contraction in 
the presence of BDNF. P-ERK1/2 level was studied via western blot.  
 
3.7.1a MAPK effect on basal activity 
Inhibition of MAPK activity with 10 uM PD98059 for 15 min incubation resulted in no 
significant change in basal tone of rabbit LM strips. Administration of PD98059 resulted in 
change of basal tone from 0.81 ± 0.03 grams to 0.78 ± 0.06 grams, P>0.05, n=8. Summary of this 
data is displayed in figure 24. 
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3.7.1b MAPK effect on CCh peak contraction 
Incubation of the strips with PD98059 for 15 min had no significant effect on 10 μM CCh 
peak contraction. Peak contraction following ERK1/2 inhibition was 97.6 % ± 13.6% of the 
control peak contraction, n=at least 6 (Fig. 25). 
 
3.7.1c MAPK effect on BDNF-enhanced cholinergic contraction  
When PD98059 was administrated 15 min before BDNF exposure, CCh peak contraction 
was similar to the contraction produced without PD98059 application, p>0.05. Mean CCh 
contractions values were viewed as percentage of control contraction, contraction following 1 hr 
BDNF incubation was 193% ± 22% of the control value, n=9, P<0.005. Pretreatment with 
PD98059 before BDNF incubation led to contraction 183% ± 19% of the control value, n=8, 
P<0.05. Summary of the DATA is depicted in figure 25. These findings indicated that the effect 
of BDNF on CCh-induced contraction does not proceed through MAPK activation. 
To test the effect of BDNF on ERK1/2 activation in intestinal smooth muscle, we 
measured the level of P-ERK1/2 in rabbit LM by western blot analysis with antibody specific to 
P-ERK1/2, and GAPDH was used to normalize against experimental variations. BDNF treatment 
of rabbit LM for 1 hr did not affect the amount of P-ERK1/2 as demonstrated in in figure 26. 
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Figure 24: Effect of ERK1/2 inhibition of basal tone 
Administration of 10 μM PD98059 for 15 min resulted in no significant inhibition of basal tone.  
Mean tension values of control strips versus PD98059 incubated strips are 0.82 ± 0.03 grams 
versus 0.75 ± 0.06 grams, P>0.05, n=8. 
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Figure 24 :  
104 
  
Figure 25: Effect of ERK1/2 inhibition of BDNF–enhanced CCh-induced contraction 
Administration of 10 uM PD98059 for at least 10 min did not significantly inhibit contraction 
induced by 10 uM CCh (CCh contraction 100% versus CCh plus PD98059 97% ± 15%, P>0.05). 
10 uM PD98059 introduced 10 min before BDNF administration did not significantly reduce the 
increase in contraction in response to BDNF 1 hr incubation. (CCh 100%;   CCh plus BDNF 
193% ± 22% CCh, BDNF plus PD98059 183% ± 19%, n=8 from at least three rabbits). *P< .05, 
**P<005. 
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Figure 25: 
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Figure 26: ERK1/2 phosphorylation in rabbit LM strips 
BDNF failed to activate ERK1/2 protein in LM. (A) Western blot analysis of ERK1/2 in rabbit 
LM treated with 10 nM BDNF for 1h showed no difference between treatment and control 
groups. GAPDH was used as the loading control. (B) Summary data indicating that BDNF did 
not significantly activate ERK1/2 in rabbit LM strips, n=3. DATA are mean values ± SEM. 
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Figure 26: 
 
 
 
 
 
 
108 
  
3.7.2 Effect of PLC-γ inhibition 
Incubation of strips with 1-10 μM U73122 (a PLC specific inhibitor) for 15 min was  
used to assess the role of PLC-γ in BDNF enhancement of CCh-induced contraction. PLC- γ 
inhibition was tested in respect to basal tone, CCh peak contraction and CCh peak contraction in 
the presence of BDNF. P-PLC- γ level was studied via western blot.  
 
3.7.2a Effect on basal tone 
To study the role of PLC- γ on intestinal rabbit LM basal activity, 1-10 μM U73122 was 
administrated for 15 min and the basal tension amplitude was compared to that before U73122 
exposure. Basal tone mean value was not significantly different being 0.83 ± .03 grams before 
U73122 and 0.81 ± 0.08 grams after U73122. The data is derived from at least three rabbits and 
the p value was greater than 0.05 (Fig. 27). These results indicate that PLC- γ has no significant 
effect on LM basal tone. 
 
3.7.2b Effect of PLC-γ on CCh-induced peak contraction 
The effect of PLC inhibition was  tested on CCh peak contraction. 10-μM U73122 
incubation for 15 min led to no significant change in CCh peak contraction. CCh peak 
contraction following U73122 incubation is 117% ± 14% of the control peak contraction before 
U73122 (P>0.05), for at least three different rabbits. Summary of data are displayed in figure 28. 
 
3.7.2c Effect of PLC-γ on BDNF-enhanced cholinergic contraction 
Administration of U73122 15 min before BDNF exposure significantly inhibited the 
enhancement of CCh peak contraction due to BDNF (Fig. 28). BDNF enhanced the CCh peak 
contraction by 88%, but when the strips were exposed to10-μM U73122 the peak contraction 
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values were comparable to those obtained with CCh alone. P value was at least less than 0.05. 
These findings demonstrate that BDNF exerts its effect on CCh-induced contraction through 
activation of PLC-γ. Next, we examined the activation of PLC- γ by BDNF in rabbit LM. 
Western blot analysis of P-PLC-γ indicated the 10 nM BDNF resulted in robust phosphorylation 
of PLC-γ following 1hr incubation (Fig. 29). Phosphorylation of PLC-γ by BDNF strengthens 
the role of PLC-γ in mediating BDNF effect on LM contraction. 
 
3.7.3 Effect of AKT inhibition 
 To test the role of AKT in BDNF augmentation of CCh peak contraction, 10 μM LY294002, a 
selective PI3K inhibitor was introduced to the organ baths 15 min before BDNF incubation. The 
contraction in respose to 10 μM CCh was compared before and after LY294002. AKT inhibition 
led to no significant change in BDNF ability to augment CCh-induced contraction (Fig. 30). P> 
0.05, n =3. 
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Figure 27: Effect of U73122 inhibition on Basal Tone 
Administration of 10 uM of U73122 had no significant effect on basal tone (.82 ± .03 grams 
versus .82 ± .08, n=12). 
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Figure 27: 
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Figure 28: Effect of PLC-γ inhibition on BDNF-enhanced CCh-induced contraction 
 Incubation of LM strips with U73122 alone had no significant effect on contraction induced by 
10 uM CCh. U73122 15 min before BDNF administration significantly reduce the effect of 
BDNF on CCh-induced contraction ( BDNF induced increase in contraction reduced from 98% 
to 11% above control (i.e. contraction induced by 10 uM CCh alone )). Values are means ± 
SEM, n=7, * P< .05, **P<001. 
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Figure 28: 
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Figure 29: BDNF activates PLC γ in rabbit LM.  
Western blot analysis of BDNF in Rabbit LM strips, (A) 10nM BDNF treatment of LM strips 
for 1 h resulted in a robust PLC-γ phosphorylation. (B) Summary graph of densitometry 
analysis showing that BDNF significantly activates PLC-γ in LM strips. Data are mean values ± 
SEM, N=3, **P<0.005 
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Figure 29:  
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Figure 28: Effect of AKT inhibition on BDNF-enhanced CCh-induced contraction 
 Incubation of LM strips with LY294002 15 min before BDNF administration had no significant 
effect on the augmentatory effect of BDNF on contraction induced by 10 uM CCh. Values are 
means ± SEM, n=3, * P> 0.05. 
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Figure 30:   
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CHAPTER 4 
Discussion 
 
4.1 Localization of BDNF in intestinal muscle tissues 
Neurotrophins are a well-known protein family in the nervous system that regulates 
diverse neuronal functions such as survival, differentiation, migration and activity-dependent 
synaptic plasticity. As a target derived neurotrophic factor, it is not surprising that neuronal 
target tissues like skin, cardiac, skeletal and smooth muscle also secrete neurotrophins [104, 
105]. Neurotrophins derived from such targets could modulate the innervation to these tissues. 
Moreover, there is increasing recognition that neurotrophins and their receptors are expressed in 
non-neuronal tissues that are not essentially associated with innervation. In this regards, 
neurotrophins have been described in a variety of smooth muscles such as airways, bladder and 
blood vesicles [105-107].   In this study, we have identified BDNF in intestinal smooth muscle 
tissues from mice, rabbit (Fig.1& 2) and human (Data are not shown).  
BDNF localization in rabbit intestinal smooth muscle cells is identified using different 
experimental approaches. BDNF protein is detectable in rabbit intestinal muscle by specific 
BDNF immunostaining, different western blotting techniques (ECL, Licore and ICW) and 
ELISA. We have demonstrated that BDNF level was higher in longitudinal compared to circular 
muscle layer in mice, rabbit and human. The BDNF protein presence in longitudinal muscle 
(LM) layer from rabbit intestine was confirmed in primary SMCs cultures by western analysis 
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and ELISA. Moreover, BDNF mRNA level was higher in rabbit longitudinal muscle 
(Fig. 3)than circular muscle. 
Currently, the explanation for the difference between BDNF level in longitudinal versus 
circular intestinal muscle has not been investigated and hence is unknown. However, it could be 
due to differences in the development of the two muscle layers [108].  
4.2 BDNF Secretion  
 This the first study to demonstrate that LM cell cultures of the intestine secrete BDNF 
constitutively.  Quantitative ELISA measurements demonstrated that at rest LM cell cultures 
secrete low levels of BDNF into the culture medium (Fig. 9, 10 & 11). Identification of SMCs as 
an paracrine organ that produces and secretes substances (like BDNF) is not a new paradigm. 
Previous reports have demonstrated that intestinal smooth muscle cells synthesize and secrete 
humoral factors such as collagen, insulin-like growth factor and cytokines [109-112]. Several 
reports have documented synthesis and secretion of neurotrophins in vascular and lung SMCs 
[107, 113]. The constitutive secretion of BDNF from intestinal LM could regulate the normal 
functional status of this muscle layer. The BDNF level could be modulated by physiological or 
pathological stimuli and thus could participate in SMCs contractility, inflammation level and 
tissue remodeling.   
In this study, we also have identified both BDNF receptors, TrkB and P75NTR in rabbit 
LM cells (Data not shown). This finding raises the possibility that BDNF released in the vicinity 
of LM cells could have an autocrine or paracrine effect on smooth muscle cells and their 
innervating neurons. 
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4.3 BDNF Modulation in Longitudinal SMCs 
This is the first study to investigate BDNF in intestinal SMCs. We have demonstrated 
that PACAP and SP induce the synthesis and release of BDNF in intestinal longitudinal SMCs 
cultures. The inducible release of BDNF reflects the nature of BDNF protein, which is secreted 
via the regulated pathway of secretion [17, 114]. 
The interaction between PACAP/SP and BDNF has been reported in several studies and 
in different tissues. In cultured neurons, the protective effect of PACAP was mediated through 
BDNF, where PACAP  induced the expression of BDNF [115]. Moreover, PACAP upregulted 
BDNF mRNA  in cortical neurons [92]. Several reports have coupled BDNF and SP, for 
example, BDNF increased SP expression in GI tract inflammation and both peptides were 
reported to be increased in different inflammation models [116, 117]. On the other hand, PACAP 
and SP are among the main relaxant and contractile neuropeptides respectively released from 
neurons that innervate smooth muscle cells making them excellent candidates for BDNF 
modulation in longitudinal SMCs. 
 
4.3.1 Regulation of BDNF protein in intestinal longitudinal SMCs cultures 
The inducible effect of PACAP on BDNF protein content in rabbit longitudinal SMCs 
cultures was measured using western blot technique. In our experimental approach, PACAP 38 
treatment at 10 nM and 100 nM produced marked increase in BDNF protein content after 24-
hour incubation. There was no difference between the two doses in their ability to induce BDNF 
protein suggesting that 10 nM PACAP is the concentration that gives the maximal response. 
Moreover, daily incubation for 48 hours with both concentrations maintained the elevated levels 
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of BDNF protein compared to control. The 48 hour levels were a little higher than that obtained 
with 24 hours. Consistent with these finding, several reports have demonstrated the effect of 
PACAP 38 on BDNF [92, 100]. Reichenstein et al. have reported that PACAP 38 at 10 nM and 
100 nM increased BDNF mRNA in rat primary cortical neurons. The up-regulation of BDNF 
protein after PACAP exposure could represent the activation of transcriptional mechanisms, 
translational and/or post-translational regulation of BDNF production.  
 BDNF protein levels were also up-regulated by SP in intestinal longitudinal primary 
SMCs cultures. 10 nM and 100 nM SP produced significant increase in BDNF content following 
24 hrs treatments. Treatment with both concentrations for 48 hrs also enhanced BDNF protein 
levels compared to cells incubated with DMEM-0 alone. The effect of SP on BDNF protein 
levels could reflect the activation of neurokinin receptors in intestinal SMCs by SP and the 
subsequent elevation of intracellular Ca
2+
 levels. We demonstrated that pretreatment of SMCs 
with BAPTA-AM prevented BDNF protein up-regulation in response to SP, indicating that an 
intracellular increase in calcium was responsible for SP-induced BDNF protein production.  The 
change in BDNF levels is presumably caused in part by alteration of de novo synthesis, as 
inferred from altered levels of BDNF mRNAs. Furthermore, intracellular Ca
2+
 was important for 
the induction of BDNF mRNA in SMCs because the chelation of cytosolic Ca
2+
 by BAPTA 
abolished the effect of SP on BDNF mRNA levels. The importance of intracellular Ca
2+ 
for 
BDNF gene transcription is well documented, it is essential for cAMP-response element (CRE) 
binding protein (CREB) phosphorylation. Intracellular Ca
2+
 leads to Ca
2+
-calmodulin-dependent 
protein kinases (CaMKs) activation, which in turn phosphorylates CREB. Phosph-CREB binds 
to a critical Ca
2+ 
response element (CRE) within the BDNF gene and activates BDNF 
transcription [118, 119]. 
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The interactions between neurotrophins and SP have been the subject of many research 
studies [42, 44, 120, 121]. SP has been implicated directly as a mediator neurogenic control of 
inflammation and the associated hypersensitivity [122-124]. In inflammation models, there is 
increase in SP, neurotrophins, and cytokines [51, 116, 117]. In this regard, BDNF and other 
neurotrophins has been demonstrated to induce SP up-regulation in different tissues [125, 126]. 
To our knowledge, this is the first report to show the opposite interaction that SP induces BDNF 
expression in SMCs cultures from rabbit intestine. Similar results were reported in airway 
smooth muscle cells, where SP at 10 nM induced up-regulation of BDNF [120].   The prolonged 
exposure of normal SMCs cultures to SP could mimic one of the conditions of a state of 
inflammation induced by SP. Whether up-regulation of BDNF in prolonged SP-incubated 
intestinal SMCs represents normal or diseased states needs further investigation.  One interesting 
possibility is that our finding that SP increases BDNF coupled with the published observation 
that BDNF increases SP expression [26, 27] sets up the possibility of a positive feedback loop to 
cause a strong elevation of both peptides.  Increase in both BDNF and SP would further sustain 
the inflammatory state and might perhaps explain some of the pathological effects of intestinal 
inflammation.   
 
4.3.2 Induction of BDNF release in intestinal longitudinal SMCs cultures 
We have provided evidence in this study that BDNF protein secretion is enhanced by 
PACAP and SP treatments in rabbit longitudinal SMCs cultures. PACAP 10 nM and 100 nM 
increased the secretion of BDNF in SMCs cultures after 24 and 48 hrs as indicated by ELISA 
BDNF measurements. The BDNF ELISA used here is very specific for BDNF with cross 
reactivity less than 3% with other neurotrophins. BDNF secretion after 48 hrs incubation with 
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both concentrations was less than that measured after 24 hrs incubation. The reduction in BDNF 
secretion could be due to BDNF protein degradation or formation of clusters of BDNF with other 
components in the cell culture medium evading quantification by ELISA. This explanation was 
documented in several reports due to the basic nature of BDNF (PI 9.1) which makes it very 
sticky [127, 128]. As stated earlier, PACAP in nanomolar concentrations activates BDNF 
expression [92, 100, 129], so the release of BDNF in response to PACAP in intestinal SMCs 
could be release of either newly formed or prestored BDNF. In intestinal SMCs, PACAP is able 
to activate cAMP, cGMP and intracellular Ca
2+ 
[130] and BDNF is known to be secreted in 
response to intracellular Ca
2+ 
elevation and to stimuli that activate AC and generate cAMP [23, 
131]. 
 We have demonstrated that SP can also induce BDNF secretion in rabbit longitudinal 
SMCs. In this study, treatment with 10 nM and 100 nM induced BDNF secretion after 24 hrs 
incubation as shown by ELISA quantification. The BDNF secretion via the two SP 
concentrations was significantly higher than the control but there was no difference between the 
concentrations indicating that 10 nM SP induced the maximal BDNF secretion. This finding is in 
agreement with other reports that SP at nanomolar concentrations can work as a growth factor 
and its affect at higher doses is weakened [120, 132, 133]. SP incubation for 48 hrs maintained 
the elevated levels of BDNF in cultured medium supernatants compared to control; however, 
they were lower in comparison to results obtained after 24 hrs. This observation is in common to 
the effect of PACAP after 48 hrs incubation on BDNF secretion, making it tempting to speculate 
that the BDNF protein nature could be the reason for the this observation.  That is, it may be 
partly degraded with time in culture. 
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 Since SP-containing neurons are more common than PACAP containing neurons, 
especially in the longitudinal muscle layer, we focused on the question of how SP regulates 
BDNF in rabbit longitudinal SMCs cultures. Our data demonstrated that SP enhanced BDNF 
mRNA, protein content and secretion. Thus, we presume that the increase in BDNF secretion 
represented a component of both newly synthesized protein in addition to preformed BDNF in 
SMCs. Intriguingly, the effect of SP on BDNF mRNA, protein synthesis and secretion all require 
elevation of intracellular Ca
2+
. The dependence of BDNF secretion on intracellular Ca
2+
 
elevation is well documented in literature. In neurons, BDNF release induced by membrane 
depolarization depends on Ca
2+
 influx through voltage gated calcium channels and Ca
2+
 
mobilization from internal stores [17, 23]. Therefore, we can speculate that SP activates its 
neurokinin receptors on intestinal SMCs resulting intracellular Ca
2+
 elevation, which is the 
hallmark of BDNF regulated release. The source of intracellular Ca
2+ 
and the downstream 
effectors require further investigation. Even though, the extracellular source of Ca
2+
 is expected 
to have critical role, as these are longitudinal SMCs. In longitudinal SMCs, entry of Ca
2+
 is an 
obligatory step for cytosolic Ca
2+
 elevation [81].   
 In conclusion, our data demonstrates that BDNF, a well-characterized growth factor that 
supports a plethora of neuronal functions, can be produced by rabbit longitudinal SMCs and this 
production is up regulated by gut neuropeptides such as PACAP and SP. The significance of this 
could be in improving our understanding of SMCs function in health and disease. For example, 
BDNF could modulate innervation to smooth muscle and/or contractility in response to 
contractile agonists.  This latter possibility was chosen for further investigation as presented in 
the following sections. 
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4.4 Effect of BDNF on longitudinal SMCs contraction induced by carbachol (CCh) and SP 
In this study, we provide evidence demonstrating a functional role of BDNF in gut 
motility. BDNF enhanced SMCs contraction induced by CCh but not SP. The effect of BDNF 
most probably is through TrkB activation and the subsequent PLC-γ phosphorylation. 
 CCh and SP initiate contraction in longitudinal and circular SMCs by increasing 
intracellular Ca
2+
. The mechanism for increasing intracellular Ca
2+ 
varies between the two cell 
types  for the intial contraction which is what was measured in the current study. In circular 
SMCs, G protein–coupled agonists initiate contraction even in the absence of extracellular Ca2+. 
Receptors activation leads to PLC phosphorylation that liberates diacylglycerol (DAG) and the 
diffusible Ca
2+
-mobilizing messenger, inositol 1, 4, 5-trisphosphate (IP3). While in longitudinal 
SMCs, extracellular Ca
2+
 is essential for contraction initiation, where Ca
2+
 influx represent the 
trigger for Ca
2+ 
mobilization for internal stores. G protein–coupled agonists in LM  activate 
cytoplasmic phospholipase A2, which in turn liberates arachidonic acid from membrane lipids.  
Arachidonic acid activates chloride channels, which induce membrane depolarization, and hence 
calcium channels opening. Ca
2+ 
influx induces cyclic ADP ribose formation and stimulates both 
Ca
2+
- and cyclic ADP ribose-induced Ca
2+
 release from internal stores [81]. 
 
4.4.1 Effect of BDNF on CCh peak contraction  
We demonstrated that BDNF enhances the peak contraction induced by CCh in rabbit 
intestinal LM strips. Early in this study, we demonstrated that intestinal LM produces BDNF. 
The function of BDNF in the gut is poorly documented. Recently, a few studies reported the 
excitatory role of BDNF in gut motility. For example, patients with amyotrophic lateral sclerosis 
and diabetic neuropathy who received Hr-Met-BDNF experienced increased gut motility, 
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diarrhea and increased bowel urgency [45, 46] .Moreover, exogenous BDNF stimulated the 
myoelectric activities of rat intestine [134] and the enhanced the peristaltic reflex induced by 
mucosal stimulation in mice [42].  
In this study, the effect of CCh on isolated rabbit LM strips was verified first. As 
expected, CCh (10
-7
 – 10-4) induces dose-dependent contractions in rabbit intestinal LM strips as 
shown in figure 17.  After that, we selected CCh 10
-5
, a submaximal dose, to test the effect of 
BDNF on CCh peak contraction.  BDNF alone failed to change significantly the basal tone of the 
strips. On the other hand, our data provide evidence that 10 nM BDNF robustly enhances the 
CCh peak contraction following 1 hr incubation, suggesting that the primary role of BDNF is to 
sensitize SMCs to CCh. The modulatory function of BDNF is a well-described behavior in many 
systems, for example exogenous BDNF alone did not initiate the peristaltic reflex but enhanced 
the reflex induced by mucosal stimulation [42]. Moreover, BDNF enhanced depolarization- 
induced release of GABA, dopamine, and 5-HT  in rat brain striatal slices, but it had no effect on 
transmitter release when added alone [135]. Our finding is consistent with the reported excitatory 
effect of BDNF in gut motility [42, 46, 134] and does not conflict with the absence of influence 
of BDNF on acetylcholine-induced contraction in mice whole mount strips from ileum reported 
by Chen et al. [48]. The differences in species, strips preparation, drug concentrations and 
incubation time could explain the difference in interpretation of the two studies. In our 
experimental setting, each strip serves as its own control, which eliminates the measured 
variations between strips. Furthermore, the strips data were analyzed in respect to the peak 
contraction only.   
 The augmented contraction of intestinal LM strips incubated with BDNF in response to 
CCh can explain the increased contractility of muscle layers associated with inflammation of the 
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GI tract. Inflammation is associated with structural and functional changes in the contractile 
apparatus of GI tract that leads to altered motor function [136, 137]. Intestinal smooth muscle 
hypercontractility is a characteristic of different models of gut inflammation [137-139]. CCh-
induced intestinal smooth muscle contraction was significantly increased after gut inflammation 
[138, 140]. Akiho et al. [138] demonstrated that infection and the subsequent gut inflammation 
increased muscarinic receptor affinity to CCh in mice longitudinal muscle cells. In line with 
these findings, airway smooth muscle cell hyper-responsiveness is a hallmark of lung 
inflammation. Moreover, BDNF upregulation contributes  to airway reactivity in 
pathophysiological states associated with airway inflammation [120]. In  this context, BDNF has 
been shown to be up-regulated in GI tract inflammation and in response to inflammatory 
cytokines [52, 116]. Therefore, the reported hypercontractility to CCh in BDNF incubated 
muscle strips shown in the present study can explain the altered motor function, which 
accompanies gut inflammation. Nevertheless, the interaction between other inflammatory 
cytokines and BDNF in CCh-induced contraction needs further investigation since the response 
to inflammation and the potential mediators is likely to be complex and multifactorial.  
 
4.4.2 The signaling pathways involved in BDNF effect on contraction induced by  CCh 
The present study indicates that BDNF augments CCh-induced LM contraction by 
activating TrkB receptors, most probably on SMCs membrane. Furthermore, TrkB activation 
leads to PLC-γ phosphorylation and subsequently sensitizing SMCs to CCh.  
BDNF acts via its high affinity TrkB receptor tyrosine kinase. We demonstrated both 
BDNF and TrkB expression in longitudinal muscle layer of rabbit intestine. Inhibition of TrkB 
using Trk specific inhibitor K252a prevented BDNF effect on CCh peak contraction in LM 
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strips. Immunoneutralization of TrkB with anti TrkB antibody also abolished the effect of 
BDNF. Furthermore,  recently reported TrkB selective agonists (LM 22A4 and 7,8-
Dihydroxyflavone) [141, 142] were introduced to the organ bath 15 min before CCh exposure 
and resulted in augmentation of peak contraction similar to that seen with BDNF (see figure 22). 
These results support the conclusion that BDNF augments CCh-induced contraction by 
activating TrkB. In line with this finding, several reports indicate that BDNF mediates its 
biological effect through TrkB receptor activation. For example, BDNF and 7, 8-
Dihydroxyflavone enhanced cholinergic neurotransmission via activation of TrkB in mice 
diaphragm muscle [143]. Moreover, BDNF augments intracellular Ca 
2+
 rise in response to Ach 
in airways smooth muscle cells by activating TrkB receptor [120]. 
It is noteworthy that inhibition of TrkB signaling via K252a had no effect on LM strips 
basal activity and CCh peak contraction in the absence of BDNF, suggesting a small contribution 
of the endogenous BDNF.  
The present study demonstrates that BDNF acts to augment CCh peak contraction in 
rabbit intestine specifically by activating PLC-γ, a downstream effector of TrkB.  A specific PLC 
inhibitor that is commonly used to block PLC activation in gut SMCs, U73122 (1-10 µM), 
abolished the augmentation effect of BDNF on CCh-induced contraction. Whereas, inhibiting 
MAP kinase with (10 µM) PD98059 had no effect. In support of this conclusion, BDNF 
treatments of LM strips robustly induce PLC-γ phosphorylation. PLC inhibition with (.1-10 µM) 
U73122 had no effect on CCh-induced contraction in the absence of BDNF, this is consistent 
with the lack of PLC-β activation in response to CCh activation of muscarinic receptors in 
intestinal longitudinal muscles [81]. Moreover, the lack of effect of U73122 on contraction by 
CCh alone indicates that its effect on BDNF enhancement of contraction is specific to PLC-γ. 
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Thus the effect of BDNF on CCh-induced contraction here could reflect the activation of PLC, a 
mechanism that is usually absent in intestinal longitudinal muscle. In this regard, we can 
speculate that BDNF acts on SMCs to activate TrkB and subsequent PLC-γ activation, leading to 
IP3 generation, which binds to IP3 receptors and triggers internal Ca
2+
 release.  
The role of AKT pathway in BDNF enhanced CCh-induced contraction was examined. 
Although BDNF induced slight phosphorylation of AKT in LM strips, AKT inhibition by 
LY294002 had no significant effect on BDNF induced enhancement of LM  strip contraction by 
CCh. This result is also inferred from the effect of U73122 which completely abolished the effect 
of BDNF on CCh-induced contraction. 
Another mechanism BDNF can contribute to CCh hyper-responsiveness is by 
upregulating muscarinic receptors insertion to the membrane. Here, our preliminary data 
suggests that BDNF enhances total CCh binding to SMCs. Total binding assay indicates that 
BDNF treatments of intestinal longitudinal SMCs led to increase in specific radioligand ([
3
H] 
Scopolamine) binding to surface M3 and M2 receptors ( data not shown). Similar effect of 
BDNF on N-methyl-D-aspartate (NMDA) glutamate receptor was reported. BDNF treatments 
increased the abundance of NMDA receptor subunits in cultured hippocampal neurons, that 
correlated with the receptors activity [144]. Furthermore, BDNF regulates membrane insertion of 
AMPA receptors and nicotinic receptors [145, 146]. Whether BDNF enhances M3 or M2 
membrane abundance or both of them needs further investigations.   
In conclusion, BDNF induces SMCs hypercontractility in response to CCh. The effect of 
BDNF is the result of TrkB activation and the subsequent phosphorylation of PLC-γ. These 
results provide new insight into the mechanisms of neurotrophin (BDNF) modulation of gut 
function, which may lead to new therapeutic avenues for treatment of gastrointestinal disorders, 
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and explain some of the patholological changes associated with inflammation such as 
hypercontractility associated with gut infection or IBD. 
 
 
 
4.5 Proposed model for BDNF in longitudinal SMCs 
Our finding indicates that intestinal longitudinal SMCs express basal level of BDNF. 
Furthermore, SP and PACAP upregulate BDNF content and can induce its secretion in a 
mechanism that involves regulation of intracellular Ca
2+
 level. In turn, secreted BDNF acts in 
autocrine manner to enhance SMCs responses to CCh by activating TrkB and the subsequent 
phosphorylation of PLC-γ. CCh induced Ca influx and BDNF induced PLC-γ activation and 
subsequent release of stored Ca could synergistically elevate intracellular Ca
2+
 and produce more 
contraction. This would interact with the BDNF induced increase the release of neurotransmitter 
form the surrounding neurons in paracrine fashion. The net effect is enhanced contraction of 
longitudinal muscle  
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Figure 30: Schematic model of BDNF interactions in intestinal longitudinal SMCs. 
In intestinal longitudinal SMCs, enteric neurons release SP or PACAP. Both neuropeptides act 
via their receptors on SMCs to elevate intracellular Ca
2+
 resulting in BDNF synthesis and 
release. Secreted BDNF activates TrkB on SMCs to potentiate their contractile response to Ach 
in a mechanism that involves PLC-γ phosphorylation.  
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Figure 30: 
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